SPT - Interim / Quarterly Report 2024

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS AND INDEPENDENT AUDITORS’ REVIEW REPORT SEPTEMBER 30, 2024 AND 2023

For the convenience of readers and for information purpose only, the auditors’ report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors’ report and financial statements shall prevail.

~1~

INDEPENDENT AUDITORS’ REVIEW REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of ScinoPharm Taiwan, Ltd.

Introduction

We have reviewed the accompanying consolidated balance sheets of ScinoPharm Taiwan, Ltd. and subsidiaries (the “Group”) as at September 30, 2024 and 2023, and the related consolidated statements of comprehensive income for the three-month and nine-month periods then ended, as well as the consolidated statements of changes in equity and of cash flows for the nine-month periods then ended, and notes to the consolidated financial statements, including a summary of material accounting policies. Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” that came into effect as endorsed by the Financial Supervisory Commission. Our responsibility is to express a conclusion on these consolidated financial statements based on our reviews.

Scope of review

Except as explained in the following paragraph, we conducted our reviews in accordance with the Standard on Review Engagements 2410, “Review of Financial Information Performed by the Independent Auditor of the Entity” of the Republic of China. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

~2~

Basis for qualified conclusion

The financial statements of certain insignificant consolidated subsidiaries and supplementary disclosures in Note 13 were not reviewed by independent auditors. Those statements reflect total － assets of $28,612 thousand and $19,737 thousand, both constituting % of the consolidated total － assets, and total liabilities of $9,576 thousand and $3,611 thousand, constituting 1% and % of the consolidated total liabilities as at September 30, 2024 and 2023, respectively, and total comprehensive income (loss) of $553 thousand, ($4,177) thousand, $2,022 thousand and ($10,091) thousand, constituting 1%, (6%), 1% and (13%) of the consolidated total comprehensive income for the threemonth and nine-month periods then ended, respectively.

Qualified conclusion

Except for the adjustments to the consolidated financial statements, if any, as might have been determined to be necessary had the financial statements of certain insignificant subsidiaries and supplementary disclosures of Note 13 been reviewed by independent auditors as described in the Basis for qualified conclusion section above, based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Group as at September 30, 2024 and 2023, and its consolidated financial performance for the three-month and nine-month periods then ended and its consolidated cash flows for the nine-month periods then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” that came into effect as endorsed by the Financial Supervisory Commission.

~3~

Yeh, Fang-Ting Independent Auditors

Lin, Tzu-Shu

PricewaterhouseCoopers, Taiwan Republic of China November 4, 2024

------------------------------------------------------------------------------------------------------------------------------The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors’ report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

~4~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

SEPTEMBER 30, 2024, DECEMBER 31, 2023 AND SEPTEMBER 30, 2023

(Expressed in thousands of New Taiwan dollars)

Assets	Notes	September 30, 2024 AMOUNT % `$` `3,975,691 34` `1,974` `-` `445,565` `4` `29,346` `-` `1,876,599 16` `157,927` `1` `6,487,102 55` `74,564` `1` `3,702,367 32` `688,527` `6` `22,614` `-` `637,515` `5` `138,290` `1` `2,385` `-` `30,940` `-` `5,297,202 45` `$` `11,784,304 100` (Continued)	December 31, 2023 AMOUNT % `$` `3,941,524` `33` `8,304` `-` `788,221` `7` `25,230` `-` `1,511,535` `13` `105,794` `1` `6,380,608` `54` `69,973` `1` `3,762,696` `32` `636,748` `5` `19,152` `-` `640,930` `6` `178,146` `2` `2,393` `-` `30,940` `-` `5,340,978` `46` `$` `11,721,586` `100`	September 30, 2023	September 30, 2023
		AMOUNT `$` `3,975,691` `1,974` `445,565` `29,346` `1,876,599` `157,927` `6,487,102` `74,564` `3,702,367` `688,527` `22,614` `637,515` `138,290` `2,385` `30,940` `5,297,202` `$` `11,784,304` (Continued)	AMOUNT `$` `3,941,524` `8,304` `788,221` `25,230` `1,511,535` `105,794` `6,380,608` `69,973` `3,762,696` `636,748` `19,152` `640,930` `178,146` `2,393` `30,940` `5,340,978` `$` `11,721,586`	AMOUNT `$` `3,994,616` `-` `363,585` `19,355` `1,642,536` `141,435` `6,161,527` `70,364` `3,652,906` `642,151` `12,296` `631,508` `363,003` `2,399` `30,940` `5,405,567` `$` `11,567,094`	%
Current assets 1100 Cash and cash equivalents 1110 Financial assets at fair value through profit or loss - current 1170 Accounts receivable, net 1200 Other receivables 130X Inventories 1410 Prepayments 11XX Total current assets Non-current assets 1517 Financial assets at fair value through other comprehensive income - non-current 1600 Property, plant and equipment 1755 Right-of-use assets 1780 Intangible assets 1840 Deferred income tax assets 1915 Prepayments for equipment 1920 Guarantee deposits paid 1980 Other financial assets - non- current 15XX Total non-current assets 1XXX Total assets	6(1) 6(2) 6(3) and 12 6(4) 6(5) 6(6)(8) and 7 6(7) 6(24) 6(6) 6(1) and 8				`35` `-` `3` `-` `14` `1`
					`53`
					`1` `32` `6` `-` `5` `3` `-` `-`
					`47`
					`100`

~5~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

SEPTEMBER 30, 2024, DECEMBER 31, 2023 AND SEPTEMBER 30, 2023

(Expressed in thousands of New Taiwan dollars)

					September 30, 2024	September 30, 2024			December 31, 2023	December 31, 2023			September 30, 2023	September 30, 2023
	Liabilities and Equity	Notes			AMOUNT	%			AMOUNT	%			AMOUNT	%
	Current liabilities
2100	Short-term borrowings	6(9)		`$`	`35,704`		`-`	`$`	`32,137`		`-`	`$`	`58,292`		`1`
2120	Financial liabilities at fair value	6(2)
	through profit or loss - current				`-`		`-`		`-`		`-`		`1,271`		`-`
2130	Contract liabilities - current	6(17)			`157,755`		`2`		`110,967`		`1`		`90,617`		`1`
2150	Notes payable				`1,603`		`-`		`1,179`		`-`		`1,553`		`-`
2170	Accounts payable				`126,966`		`1`		`101,278`		`1`		`140,792`		`1`
2200	Other payables	6(10)			`341,918`		`3`		`403,739`		`3`		`366,080`		`3`
2230	Current income tax liabilities	6(24)			`11,803`		`-`		`62,597`		`1`		`19,315`		`-`
2280	Lease liabilities - current				`18,286`		`-`		`17,556`		`-`		`17,893`		`-`
21XX	Total current liabilities				`694,035`		`6`		`729,453`		`6`		`695,813`		`6`
	Non-current liabilities
2570	Deferred income tax liabilities	6(24)			`395`		`-`		`1,661`		`-`		`792`		`-`
2580	Lease liabilities - non-current				`622,136`		`5`		`570,231`		`5`		`572,728`		`5`
2640	Net defined benefit liabilities -	6(11)
	non-current				`23,489`		`-`		`54,514`		`1`		`54,495`		`-`
2645	Guarantee deposits received				`4,343`		`-`		`1,297`		`-`		`884`		`-`
25XX	Total non-current
	liabilities				`650,363`		`5`		`627,703`		`6`		`628,899`		`5`
2XXX	Total liabilities				`1,344,398`	`11`			`1,357,156`	`12`			`1,324,712`	`11`
	Equity attributable to owners of
	the parent
	Share capital	6(12)
3110	Common stock				`7,907,392`	`67`			`7,907,392`	`68`			`7,907,392`	`68`
3200	Capital surplus	6(13)			`1,294,689`	`11`			`1,294,689`	`11`			`1,294,689`	`11`
	Retained earnings	6(15)
3310	Legal reserve				`783,817`		`7`		`755,145`		`6`		`755,145`		`7`
3320	Special reserve				`185,856`		`2`		`98,176`		`1`		`98,176`		`1`
3350	Unappropriated earnings				`383,318`		`3`		`494,884`		`4`		`337,839`		`3`
3400	Other equity interest	6(16)	`(`		`115,166 )(`		`1) (`		`185,856) (`		`2)(`		`150,859) (`		`1)`
3XXX	Total equity				`10,439,906`	`89`			`10,364,430`	`88`			`10,242,382`	`89`
	Significant contingent liabilities	9
	and unrecognised contract
	commitments
3X2X	Total liabilities and equity			`$`	`11,784,304`	`100`		`$`	`11,721,586`	`100`		`$`	`11,567,094`	`100`

The accompanying notes are an integral part of these consolidated financial statements.

~6~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

(Expressed in thousands of New Taiwan dollars, except for earnings per share amount)

						Three months ended	Three months ended	Three months ended	September 30			Nine months ended	Nine months ended	Nine months ended	September 30
						2024			2023			2024			2023
	Items		Notes			AMOUNT	%		AMOUNT	%		AMOUNT	%		AMOUNT	%
4000	Operating revenue	6(17)			`$`	`724,223`	`100`	`$`	`659,588`	`100`	`$`	`2,369,808`	`100`	`$`	`2,062,919`	`100`
5000	Operating costs	6(4)(11)(22)(2
		3)		`(`		`445,235 ) (`	`61) (`		`428,110 ) (`	`65) (`		`1,446,744 ) (`	`61) (`		`1,304,605) (`	`63 )`
5900	Net operating margin					`278,988`	`39`		`231,478`	`35`		`923,064`	`39`		`758,314`	`37`
	Operating expenses	6(7)(11)(22)(2
		3), 7 and 12
6100	Selling expenses			`(`		`29,236 ) (`	`4) (`		`31,969 ) (`	`5) (`		`109,892 ) (`	`5) (`		`111,453) (`	`5 )`
6200	General and administrative
	expenses			`(`		`80,819 ) (`	`11) (`		`88,672 ) (`	`13) (`		`266,460 ) (`	`11) (`		`261,983) (`	`13 )`
6300	Research and development
	expenses			`(`		`135,971 ) (`	`19) (`		`82,100 ) (`	`13) (`		`290,211 ) (`	`12) (`		`260,459) (`	`13 )`
6450	Expected credit loss			`(`		`1,126 )`	`- (`		`1,262 )`	`- (`		`1,681 )`	`- (`		`1,531)`	`-`
6000	Total operating expenses			`(`		`247,152 ) (`	`34) (`		`204,003 ) (`	`31) (`		`668,244 ) (`	`28) (`		`635,426) (`	`31 )`
6900	Operating profit					`31,836`	`5`		`27,475`	`4`		`254,820`	`11`		`122,888`	`6`
	Non-operating income and
	expenses
7100	Interest income	6(18)				`15,064`	`2`		`13,198`	`2`		`45,238`	`2`		`39,817`	`2`
7010	Other income	6(19)				`2,376`	`-`		`1,666`	`-`		`4,446`	`-`		`10,193`	`-`
7020	Other gains and losses	6(2)(6)(8)(20)
		and	12	`(`		`13,405 ) (`	`2) (`		`1,027 )`	`-`		`722`	`- (`		`7,957)`	`-`
7050	Finance costs	6(7)(21)		`(`		`1,934 )`	`- (`		`2,244 )`	`- (`		`6,001 )`	`- (`		`7,055)`	`-`
7000	Total non-operating income
	and expenses					`2,101`	`-`		`11,593`	`2`		`44,405`	`2`		`34,998`	`2`
7900	Profit before income tax					`33,937`	`5`		`39,068`	`6`		`299,225`	`13`		`157,886`	`8`
7950	Income tax expense	6(24)		`(`		`6,834 ) (`	`1) (`		`8,349 ) (`	`1) (`		`57,217 ) (`	`3) (`		`28,208) (`	`2 )`
8200	Profit for the period				`$`	`27,103`	`4`	`$`	`30,719`	`5`	`$`	`242,008`	`10`	`$`	`129,678`	`6`
	Other comprehensive income
	(loss)
	Components of other
	comprehensive income (loss)
	that will not be reclassified to
	profit or loss
8316	Unrealised gain (loss) from	6(5)(16)
	equity instruments measured
	at fair value through other
	comprehensive income				`$`	`25,202`	`3 ($`		`10,270 ) (`	`2)`	`$`	`4,591`	`- ($`		`42,252) (`	`2 )`
	Components of other
	comprehensive income (loss)
	that will be reclassified to
	profit or loss
8361	Financial statements	6(16)
	translation differences of
	foreign operations					`15,637`	`2`		`45,288`	`7`		`66,099`	`3 (`		`10,431)`	`-`
8300	Total other comprehensive
	income (loss) for the period				`$`	`40,839`	`5`	`$`	`35,018`	`5`	`$`	`70,690`	`3 ($`		`52,683) (`	`2 )`
8500	Total comprehensive income for
	the period				`$`	`67,942`	`9`	`$`	`65,737`	`10`	`$`	`312,698`	`13`	`$`	`76,995`	`4`
	Profit attributable to:
8610	Owners of the parent				`$`	`27,103`	`4`	`$`	`30,719`	`5`	`$`	`242,008`	`10`	`$`	`129,678`	`6`
	Comprehensive income
	attributable to:
8710	Owners of the parent				`$`	`67,942`	`9`	`$`	`65,737`	`10`	`$`	`312,698`	`13`	`$`	`76,995`	`4`
	Earnings per share (in dollars)	6(25)
9750	Basic				`$`		`0.03`	`$`		`0.04`	`$`		`0.31`	`$`		`0.16`
9850	Diluted				`$`		`0.03`	`$`		`0.04`	`$`		`0.31`	`$`		`0.16`

The accompanying notes are an integral part of these consolidated financial statements.

~7~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

(Expressed in thousands of New Taiwan dollars)

Notes			Equity a	ttributable to owners o	f	the parent
	Share capital - common stock	Capital reserve		Retained Earnings			Other EquityInterest
			Legal reserve	Special reserve		Unappropriated earnings	Financial statements translation differences of foreign operations	Unrealised (losses) gains from financial assets measured at fair value through other comprehensive income
6(5)(16) 6(15) 6(5)(16) 6(15)	`$` `7,907,392` `-` `-` `-` `-` `-` `-` `$` `7,907,392` `$` `7,907,392` `-` `-` `-` `-` `-` `-` `$` `7,907,392`	`$` `1,294,689` `-` `-` `-` `-` `-` `-` `$` `1,294,689` `$` `1,294,689` `-` `-` `-` `-` `-` `-` `$` `1,294,689`	`$` `719,584` `-` `-` `-` `35,561` `-` `-` `$` `755,145` `$` `755,145` `-` `-` `-` `28,672` `-` `-` `$` `783,817`	`$` `61,125` `-` `-` `-` `-` `37,051` `-` `$` `98,176` `$` `98,176` `-` `-` `-` `-` `87,680` `-` `$` `185,856`	`$` `565,439` `129,678` `-` `129,678` `(` `35,561 )` `(` `37,051 )` `(` `284,666 )` `$` `337,839` `$` `494,884` `242,008` `-` `242,008` `(` `28,672 )` `(` `87,680 )` `(` `237,222 )` `$` `383,318`		`($` `43,119` `)` `-` `(` `10,431` `)` `(` `10,431` `)` `-` `-` `-` `($` `53,550` `)` `($` `88,156` `)` `-` `66,099` `66,099` `-` `-` `-` `($` `22,057` `)`	`($` `55,057 )` `-` `(` `42,252 )` `(` `42,252 )` `-` `-` `-` `($` `97,309 )` `($` `97,700 )` `-` `4,591` `4,591` `-` `-` `-` `($` `93,109 )`	`$` `10,450,053` `129,678` `(` `52,683` `)` `76,995` `-` `-` `(` `284,666` `)` `$` `10,242,382` `$` `10,364,430` `242,008` `70,690` `312,698` `-` `-` `(` `237,222` `)` `$` `10,439,906`

The accompanying notes are an integral part of these consolidated financial statements.

~8~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

(Expressed in thousands of New Taiwan dollars)

CASH FLOWS FROM OPERATING ACTIVITIES
Profit before tax
Adjustments
Adjustments to reconcile profit (loss)
Loss on valuation of financial assets and
liabilities at fair value through profit or loss
Expected credit loss

Loss on (reversal of allowance for) inventory
market price decline

Depreciation of property, plant and equipment

Depreciation of right-of-use assets

Gain on reversal of impairment loss

Loss on disposal of property, plant and
equipment

Amortisation

Interest income

Interest expense

Changes in operating assets and liabilities
Changes in operating assets
Accounts receivable
Other receivables
Inventories
Prepayments
Changes in operating liabilities
Contract liabilities - current
Notes payable
Accounts payable
Other payables
Net defined benefit liabilities - non-current
Cash inflow generated from operations
Interest received
Interest paid
Income tax paid
Net cash flows from operating activities Nine months ended September 30
Notes
2024
2023
$
299,225 $
157,886
6,330
910
12
1,681
1,531
6(4)
40,049 (
25,354 )
6(6)(22)
345,001
327,313
6(7)(22)
12,928
11,878
6(6)(8)(20)
- (
27 )
6(20)
4,278
386
6(22)
6,876
4,752
6(18)
(
45,238 ) (
39,817 )
6(21)
6,001
7,055
340,970
270,139
(
2,809 )
1,449
(
408,513 ) (
427,901 )
(
51,503 ) (
9,238 )
46,788
22,865
424
318
25,688
15,528
(
37,101 ) (
54,768 )
(
31,025 ) (
19,996 )
560,050
244,909
43,931
37,295
(
5,997 ) (
7,068 )
(
101,714 ) (
102,481 )
496,270
172,655

(Continued)

~9~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

(Expressed in thousands of New Taiwan dollars)

CASH FLOWS FROM INVESTING ACTIVITIES
Decrease in other financial assets - current
Cash paid for acquisition of property, plant and
equipment

Proceeds from disposal of property, plant and
equipment
Acquisition of intangible assets
Cash paid for prepayments of equipment

Decrease in guarantee deposits paid
Net cash flows used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Increase in short-term borrowings

Decrease in short-term borrowings

Repayment of the principal portion of lease
liabilities

Increase (decrease) in guarantee deposits received

Payment of cash dividends

Net cash flows used in financing activities
Effect of foreign exchange rate changes
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period

Cash and cash equivalents at end of period Nine months ended September 30
Notes
2024
2023
$
- $
51,132
6(26)
(
88,675 ) (
54,944 )
6,204
136
(
9,980 ) (
7,133 )
6(26)
(
141,979 ) (
146,607 )
8
151
(
234,422 ) (
157,265 )
6(27)
35,250
63,407
6(27)
(
33,084 ) (
82,081 )
6(27)
(
9,350 ) (
8,453 )
6(27)
2,974 (
1,466 )
6(15)
(
237,222 ) (
284,666 )
(
241,432 ) (
313,259 )
13,751 (
2,224 )
34,167 (
300,093 )
6(1)
3,941,524
4,294,709
6(1)
$
3,975,691 $
3,994,616

The accompanying notes are an integral part of these consolidated financial statements.

~10~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2024 AND 2023

(Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

1. HISTORY AND ORGANISATION

(1) ScinoPharm Taiwan, Ltd. (the “Company”) was incorporated as a company limited by shares under the provisions of the Company Act of the Republic of China (R.O.C.) on November 11, 1997. The Company and its subsidiaries (the “Group”) are primarily engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade and research, development, produce, manufacture and sales of Active Pharmaceutical Ingredients (“API”), albumin medicines, oligonucleotide medicines, peptide medicines, injections and new small molecule drugs, as well as the provision of related consulting and technical services and international trade for the above products. In addition, the Company sells the chemical material which is reprocessed from the material recycled from the Company’s manufacturing process. For more information regarding the manufacturing and trading activities the Group are engaged in, refer to Note 4(3), “Basis of consolidation”.
(2) The common shares of the Company have been listed on the Taiwan Stock Exchange since September 2011.
(3) Uni-President Enterprises Corp., the Company’s ultimate parent company, holds 37.94% equity interest in the Company.
THE DATE OF AUTHORIZATION FOR ISSUANCE OF THE CONSOLIDATED FINANCIAL

STATEMENTS AND PROCEDURES FOR AUTHORIZATION

These consolidated financial statements were authorized for issuance by the Board of Directors on November 4, 2024.
APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS
(1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards (“IFRS[®] ”) Accounting Standards that came into effect as endorsed by the Financial Supervisory Commission (“FSC”)

New standards, interpretations and amendments endorsed by the FSC and became effective from 2024 are as follows:

Effective date by International Accounting New Standards, Interpretations and Amendments Standards Board (“IASB”) Amendments to IFRS 16, ‘Lease liability in a sale and leaseback’ January 1, 2024 Amendments to IAS 1, ‘Classification of liabilities as current January 1, 2024 or non-current’

~11~

Effective date by International Accounting New Standards, Interpretations and Amendments Standards Board (“IASB”) Amendments to IAS 1, ‘Non-current liabilities with covenants’ January 1, 2024 Amendments to IAS 7 and IFRS 7, ‘Supplier finance arrangements’ January 1, 2024

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

(2) Effect of new issuances of or amendments to IFRS Accounting Standards as endorsed by the FSC but not yet adopted by the Group

New standards, interpretations and amendments endorsed by the FSC and became effective from 2025 are as follows:

Effective date by New Standards, Interpretations and Amendments IASB Amendments to IAS 21, ‘Lack of Exchangeability’ January 1, 2025

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

(3) IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

New standards, interpretations and amendments issued by IASB but not yet included in the IFRS Accounting Standards as endorsed by the FSC are as follows:

==> picture [485 x 31] intentionally omitted <==

----- Start of picture text -----

Effective date by
New Standards, Interpretations and Amendments IASB
----- End of picture text -----

New Standards, Interpretations and Amendments	Effective date by IASB
Amendments to IFRS 9 and IFRS 7, ‘Amendments to the classification	January 1, 2026
and measurement of financial instruments’
Amendments to IFRS 10 and IAS 28, ‘Sale or contribution of assets	To be determined by
between an investor and its associate or joint venture’	IASB
IFRS 17, ‘Insurance contracts’	January 1, 2023
Amendments to IFRS 17, ‘Insurance contracts’	January 1, 2023
Amendment to IFRS 17, ‘Initial application of IFRS 17 and IFRS 9 –	January 1, 2023
comparative information’
IFRS 18, ‘Presentation and disclosure in financial statements’	January 1, 2027
IFRS 19, ‘Subsidiaries without public accountability: disclosures’	January 1, 2027
IFRS Accounting Standards「Annual Improvements – Volume 11」	January 1, 2026

Except for the following, the above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment. IFRS 18, ‘Presentation and disclosure in financial statements’

IFRS 18, ‘Presentation and disclosure in financial statements’ replaces IAS 1. The standard introduces a defined structure of the statement of profit or loss, disclosure requirements related to managementdefined performance measures, and enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes.

~12~

4. SUMMARY OF MATERIAL ACCOUNTING POLICIES

Except for the compliance statement, basis of preparation, basis of consolidation and the additional descriptions described below, the other principal accounting policies are in agreement with Note 4 of the consolidated financial statements for the year ended December 31, 2023. These policies have been consistently applied to all the periods presented, unless otherwise stated.

(1) Compliance statement

A. The consolidated financial statements of the Group have been prepared in accordance with the “Regulations Governing the Preparation of Financial Reports by Securities Issuers”, and IAS 34, ‘Interim Financial Reporting’ that came into effect as endorsed by the FSC.
B. The consolidated financial statements should be read together with the consolidated financial statements for the year ended December 31, 2023.

(2) Basis of preparation

A. Except for the following items, these consolidated financial statements have been prepared under the historical cost convention:
(a) Financial assets and financial liabilities (including derivative instruments) at fair value through profit or loss.
(b) Financial assets at fair value through other comprehensive income.
(c) Defined benefit liabilities recognised based on the net amount of pension fund assets less present value of defined benefit obligation.
B. The preparation of financial statements in conformity with International Financial Reporting Standards, International Accounting Standards, IFRIC[®] Interpretations and SIC[®] Interpretations that came into effect as endorsed by the FSC (collectively referred herein as the “IFRSs”) requires that use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 5.

(3) Basis of consolidation

A. Basis for preparation of consolidated financial statements:
The basis for preparation of these consolidated financial statements is consistent with those for the preparation of consolidated financial statements for the year ended December 31, 2023.

~13~

B. Subsidiaries included in the consolidated financial statements:

==> picture [468 x 58] intentionally omitted <==

----- Start of picture text -----

Percentage owned by the
Company
Name of Name of Business September 30, December 31, September 30,
Investors Subsidiaries Activities 2024 2023 2023 Note
----- End of picture text -----

Investors	Subsidiaries	Activities	2024	2023	2023	Note
ScinoPharm	SPT International,	Professional	100.00	100.00	100.00	`－`
Taiwan, Ltd.	Ltd.	investment
ScinoPharm	ScinoPharm	Professional	100.00	100.00	100.00	(Note)
Taiwan, Ltd.	Singapore	investment
	Pte Ltd.
SPT	SciAnda	Research,	100.00	100.00	100.00	`－`
International,	(Changshu)	development
Ltd.	Pharmaceuticals,	and manufacture
	Ltd.	of API and new
		drugs, sales of
		self-produced
		products, etc.
SPT	SciAnda	Import, export	100.00	100.00	100.00	(Note)
International,	Shanghai	and sales of
Ltd.	Biochemical	API and
	Technology,	intermediates,
	Ltd.	etc.

Note : The financial statements of the entity as of and for the nine-month periods ended September

30, 2024 and 2023 were not reviewed by independent auditors as the entity did not meet the definition of a significant subsidiary.

C. Subsidiaries not included in the consolidated financial statements: None.
D. Adjustments for subsidiaries with different balance sheet dates: None.
E. Significant restrictions: None.
F. Subsidiaries that have non-controlling interests that are material to the Group: None.

(4) Employee benefits

Defined benefit plans

Pension cost for the interim period is calculated on a year-to-date basis by using the pension cost rate derived from the actuarial valuation at the end of the prior financial year, adjusted for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-off events. Also, the related information is disclosed accordingly.

(5) Income tax

The interim period income tax expense is recognised based on the estimated average annual effective income tax rate expected for the full financial year applied to the pretax income of the interim period, and the related information is disclosed accordingly.

~14~

5. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY

There have been no significant changes during the period. Refer to Note 5 of the consolidated financial statements for the year ended December 31, 2023.

6. DETAILS OF SIGNIFICANT ACCOUNTS

(1) CASH AND CASH EQUIVALENTS

September30,2024 Cash: Cash on hand 128 $ Checking accounts and demand deposits 237,063 237,191 Cash equivalents: Time deposits 3,648,500 Bills under repurchase agreements 90,000 3,738,500 3,975,691 $	December31,2023 September30,2023 134 $ 128 $ 152,890 125,988 153,024 126,116 3,648,500 3,648,500 140,000 220,000 3,788,500 3,868,500 3,941,524 $ 3,994,616 $

A. The Group transacts with a variety of financial institutions all with high credit quality to disperse credit risk, so it expects that the probability of counterparty default is remote.
B. Details of the Group’s time deposits pledged to others as collateral (listed as “Other financial assets
non-current”) as of September 30, 2024, December 31, 2023, and September 30, 2023 are provided in Note 8, “Pledged assets”.

(2) FINANCIAL ASSETS AND LIABILITIES AT FAIR VALUE THROUGH PROFIT OR LOSS

Items	September	30,2024	December	31,2023	September	September	30,2023
Current items:
Financial assets (liabilities)
mandatorily measured at fair
value through profit or loss
Derivatives	$	1,974	$	8,304	($		1,271)
Non-current items:
Financial assets mandatorily
measured at fair value through
profit or loss
Unlisted stocks	$	4,620	$	4,620		$	4,620
Valuation adjustment	(	4,620)	(	4,620)	(		4,620)
	$	-	$	-		$	-

A. The Group recognised net gain (loss) of $1,506, ($11,265), ($21,178) and ($18,967) on financial assets and liabilities at fair value through profit or loss (listed as “ Other gains and losses”) for the three-month and nine-month periods ended September 30, 2024 and 2023, respectively.

~15~

B. The Group entered into contracts relating to derivative financial assets and liabilities which were not accounted for under hedge accounting. The information is listed below (Units in thousands of currencies indicated):

==> picture [469 x 180] intentionally omitted <==

----- Start of picture text -----

September 30, 2024
Items Contract amount Contract period
Forward foreign exchange contracts USD 6,360 8.2024~11.2024
December 31, 2023
Items Contract amount Contract period
Forward foreign exchange contracts USD 11,860 11.2023~3.2024
CNY 4,300 12.2023~1.2024
September 30, 2023
Items Contract amount Contract period
Forward foreign exchange contracts USD 3,640 8.2023~11.2023
----- End of picture text -----

The Group entered into forward foreign exchange contracts to hedge exchange rate risk of operating activities. However, these forward foreign exchange contracts are not accounted for under hedge accounting.

C. The Group has no financial assets at fair value through profit or loss pledged to others as of September 30, 2024, December 31, 2023, and September 30, 2023.
(3) ACCOUNTS RECEIVABLE, NET

	September30,2024	September30,2024	December	December	31,2023	September	30,2023
Accounts receivable	$	447,482		$	788,452	$	365,427
Less: Loss allowance	(	1,917)	(		231)	(	1,842)
	$	445,565		$	788,221	$	363,585
A. The ageing analysis of accounts	receivable is as follows:
	September30,2024		December		31,2023	September	30, 2023
Not past due	$	332,958		$	696,509	$	324,727
Less than 30 days		81,468			67,927		37,649
Between 31 to 90 days		30,987			22,686		1,242
Between 91 to 180 days		316			1,330		-
Over 181 days		1,753			-		1,809
	$	447,482		$	788,452	$	365,427

The above ageing analysis is based on past due date.

B. As of September 30, 2024, December 31, 2023, and September 30, 2023, accounts receivable arose from contracts with customers. As of January 1, 2023, the balance of receivables from contracts with customers amounted to $635,566.
C. As of September 30, 2024, December 31, 2023, and September 30, 2023, the Group does not hold any collateral as security.

~16~

D. As of September 30, 2024, December 31, 2023, and September 30, 2023, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the Group’s notes and accounts receivable was the book value amount.
E. Information relating to credit risk of accounts receivable is provided in Note 12(2), “Financial instruments”.

(4) INVENTORIES

instruments”. INVENTORIES
Raw materials Supplies Work in process Finished goods Raw materials Supplies Work in process Finished goods Raw materials Supplies Work in process Finished goods		September30,2024
	Allowance for Cost market price decline 380,299 $ 71,014) ($ 55,655 4,645) ( 645,705 101,430) ( 1,241,463 269,434) ( 2,323,122 $ 446,523) ($ December31,2023		Bookvalue
			309,285 $ 51,010 544,275 972,029
			1,876,599 $

	Allowance for Cost marketprice decline 364,396 $ 67,533) ($ 43,619 5,216) ( 544,873 96,287) ( 961,721 234,038) ( 1,914,609 $ 403,074) ($ September30,2023		Bookvalue
			296,863 $ 38,403 448,586 727,683
			1,511,535 $

	Allowance for Cost market price decline 456,295 $ 60,067) ($ 43,489 4,215) ( 564,616 87,097) ( 930,640 201,125) ( 1,995,040 $ 352,504) ($		Bookvalue
			396,228 $ 39,274 477,519 729,515
			1,642,536 $

~17~

The cost of inventories recognised as expense for the period:

		Forthe three-monthperiods ended September30,	Forthe three-monthperiods ended September30,	Forthe three-monthperiods ended September30,	Forthe three-monthperiods ended September30,	Forthe three-monthperiods ended September30,
			2024			2023
Cost of goods sold		$	292,118		$	296,075
Loss on scrap inventory			-			41,756
Loss on physical inventory			156			141
Under applied manufacturing overhead			114,903			102,112
Loss on (reversal of allowance for)
inventory market price decline (Note)			17,958	(		19,758)
Revenue from sale of scraps	(		462)	(		629)
		$	424,673		$	419,697
		For the nine-monthperiods endedSeptember30,
			2024			2023
Cost of goods sold		$	1,057,298		$	899,077
Loss on scrap inventory			-			59,851
Loss on physical inventory			559			511
Under applied manufacturing overhead			316,862			338,990
Loss on (reversal of allowance for)
inventory market price decline (Note)			40,049	(		25,354)
Revenue from sale of scraps	(		1,375)	(		1,718)
		$	1,413,393		$	1,271,357

Note: For the three-month and nine-month periods ended September 30, 2023, the Group scrapped certain inventories which could no longer be used for commercial mass production, resulting to a reversal inventory write-down.

(5) FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME -

NON-CURRENT

NON-CURRENT
Items	September	30,2024	December	31,2023	September	30, 2023
Equity instruments
Unlisted stocks	$	167,673	$	167,673	$	167,673
Valuation adjustment	(	93,109)	(	97,700)	(	97,309)
	$	74,564	$	69,973	$	70,364

A. The Group has elected to classify investments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. The fair value of such investments is the book value as of September 30, 2024, December 31, 2023, and September 30, 2023.

~18~

B. Amounts recognised in other comprehensive income in relation to the financial assets at fair value through other comprehensive income are listed below:

Equity instruments at fair value through other	Forthe three-monthperiods ended September30,	Forthe three-monthperiods ended September30,	Forthe three-monthperiods ended September30,	Forthe three-monthperiods ended September30,
comprehensive income		2024		2023
Fair value change recognised in other
comprehensive income	$	25,202	($	10,270)
Equity instruments at fair value through other	For the nine-month periods ended September 30,
comprehensive income		2024		2023
Fair value change recognised in other
comprehensive income	$	4,591	($	42,252)

C. The Group has no financial assets at fair value through other comprehensive income pledged to others as of September 30, 2024, December 31, 2023, and September 30, 2023.

~19~

(6) PROPERTY, PLANT AND EQUIPMENT

Machinery and
Transportation
Office
Other
January 1, 2024
Buildings
equipment
equipment
equipment
equipment
Cost
4,249,075
$ 5,998,911
$ 26,907
$ 244,141
$ 165,103
$ Accumulated depreciation
1,875,104)
(
4,772,711)
(
21,402)
(
195,193)
(
131,732)
(
Accumulated impairment
-
3,014)
(
-
-
-
2,373,971
$ 1,223,186
$ 5,505
$ 48,948
$ 33,371
$ For the nine-month period ended
September 30, 2024
At January 1
2,373,971
$ 1,223,186
$ 5,505
$ 48,948
$ 33,371
$ Additions
-
136
-
18
-
Reclassified from prepayments
for equipment
-
-
-
-
-
Reclassified upon completion
25,829
184,834
1,154
14,164
2,967
Depreciation charge
141,562)
(
186,687)
(
1,277)
(
12,938)
(
2,537)
(
Disposals－Cost
9,300)
(
40,042)
(
351)
(
15,224)
(
1,069)
(
' －Accumulated depreciation
2,046
36,907
351
15,202
998
Net currency exchange differences
30,666
13,817
126
705
1,113
At September 30
2,281,650
$ 1,232,151
$ 5,508
$ 50,875
$ 34,843
$ September 30, 2024
Cost
4,310,459
$ 6,177,089
$ 27,990
$ 246,216
$ 173,640
$ Accumulated depreciation
2,028,809)
(
4,941,924)
(
22,482)
(
195,341)
(
138,797)
(
Accumulated impairment
-
3,014)
(
-
-
-
2,281,650
$ 1,232,151
$ 5,508
$ 50,875
$ 34,843
$

~20~

Machinery and
Transportation
Office
Other
January 1, 2023
Buildings
equipment
equipment
equipment
equipment
Cost
4,094,506
$ 5,846,575
$ 25,270
$ 220,531
$ 160,003
$ Accumulated depreciation
1,705,956)
(
4,603,390)
(
21,775)
(
190,718)
(
134,271)
(
Accumulated impairment
-
3,015)
(
-
-
-
2,388,550
$ 1,240,170
$ 3,495
$ 29,813
$ 25,732
$ For the nine-month period ended
September 30, 2023
At January 1
2,388,550
$ 1,240,170
$ 3,495
$ 29,813
$ 25,732
$ Additions
-
-
1,118
19
879
Reclassified from prepayments
for equipment
-
-
-
-
-
Reclassified upon completion
16,349
64,082
2,492
20,699
2,538
Depreciation charge
134,538)
(
179,479)
(
922)
(
11,190)
(
1,184)
(
Disposals－Cost
2,540)
(
41,967)
(
1,772)
(
3,217)
(
630)
(
' －Accumulated depreciation
2,540
41,852
1,595
3,013
604
Reversal of impairment loss
-
27
-
-
-
Net currency exchange differences
5,102)
(
1,889)
(
19)
(
62)
(
104)
(
At September 30
2,265,259
$ 1,122,796
$ 5,987
$ 39,075
$ 27,835
$ September 30, 2023
Cost
4,101,440
$ 5,864,248
$ 27,055
$ 237,615
$ 161,808
$ Accumulated depreciation
1,836,181)
(
4,738,464)
(
21,068)
(
198,540)
(
133,973)
(
Accumulated impairment
-
2,988)
(
-
-
-
2,265,259
$ 1,122,796
$ 5,987
$ 39,075
$ 27,835
$

~21~

A. The Group has not capitalised borrowing costs as part of property, plant and equipment for the three-month and nine-month periods ended September 30, 2024 and 2023.
B. The Group’s property, plant and equipment were owner-occupied for the nine-month periods ended September 30, 2024 and 2023.
C. As of September 30, 2024, December 31, 2023, and September 30, 2023, the Group has not pledged any property, plant and equipment as collateral.
－
(7) LEASING ARRANGEMENTS LESSEE
A. The Group leases land and buildings and structures. Rental contracts are typically made for periods of 50 (including the option to extend the leases) and 2 years. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions, with no restrictions other than the use of the subject matter of the lease in accordance with relevant laws and regulations.
B. Short-term leases with a lease term of 12 months or less pertain to office premises and low-value assets pertain to computers.
C. The carrying amount of right-of-use assets and the depreciation charge are as follows:

The carrying amount	of right-of-use assets and	the depreciation charge are as follows:	e as follows:
Land Buildings and structures Land Buildings and structures Land Buildings and structures	September30,2024 Carrying amount 688,527 $ - 688,527 $	December31,2023 September30,2023 Carrying amount Carrying amount 635,741 $ 640,808 $ 1,007 1,343 636,748 $ 642,151 $ Forthe three-monthperiods ended September30,	September30,2023
			Carrying amount
			640,808 $ 1,343
			642,151 $
		2024 2023 Depreciationcharge Depreciationcharge 3,980 $ 3,621 $ 335 336 4,315 $ 3,957 $ Forthenine-monthperiods ended September30,	2023
			Depreciationcharge
			3,621 $ 336
			3,957 $
		2024 Depreciationcharge 11,921 $ 1,007 12,928 $	2023
			Depreciationcharge
			10,871 $ 1,007
			11,878 $

D. For the three-month and nine-month periods ended September 30, 2024 and 2023, there were no －－
additions to right-of-use assets; the remeasurements of right-of-use assets were $ , $ , $61,985 －
and $ , respectively.

~22~

E. The information on income and expense accounts relating to lease contracts is as follows:

	Forthe three-monthperiods ended September30,	Forthe three-monthperiods ended September30,	Forthe three-monthperiods ended September30,	Forthe three-monthperiods ended September30,
		2024		2023
Items affecting profit or loss
Interest expense on lease liabilities	$	1,815	$	1,676
Expense on short-term lease contracts		220		519
Expense on leases of low-value assets		1,068		836
	Forthenine-monthperiods ended September30,
		2024		2023
Items affecting profit or loss
Interest expense on lease liabilities	$	5,473	$	5,052
Expense on short-term lease contracts		461		823
Expense on leases of low-value assets		3,143		2,444

F. For the nine-month periods ended September 30, 2024 and 2023, the Group’s total cash outflow for leases were $18,427 and $16,772, respectively.

(8) Impairment of non-financial assets

－－
A. The Group recognised the reversal of impairment loss amounting to $ , $27, $ and $27 for the three-month and nine-month periods ended September 30, 2024 and 2023, respectively (listed as “Other gains and losses”) as some of the idle machineries were again utilised in production. For details of accumulated impairment, refer to Note 6(6).
B. The reversal of impairment loss reported by operating segments is as follows:

Recognised in profit or loss Recognised in other comprehensive income Recognised in profit or loss Recognised in other comprehensive income - $ - $ 27 $ - $ For the three-monthperiods endedSeptember30, 2024 2023 Forthenine-monthperiods ended September30,	Recognised in profit or loss Recognised in other comprehensive income Recognised in profit or loss Recognised in other comprehensive income - $ - $ 27 $ - $ For the three-monthperiods endedSeptember30, 2024 2023 Forthenine-monthperiods ended September30,	Recognised in profit or loss Recognised in other comprehensive income Recognised in profit or loss Recognised in other comprehensive income - $ - $ 27 $ - $ For the three-monthperiods endedSeptember30, 2024 2023 Forthenine-monthperiods ended September30,	Recognised in profit or loss Recognised in other comprehensive income Recognised in profit or loss Recognised in other comprehensive income - $ - $ 27 $ - $ For the three-monthperiods endedSeptember30, 2024 2023 Forthenine-monthperiods ended September30,	Recognised in profit or loss Recognised in other comprehensive income Recognised in profit or loss Recognised in other comprehensive income - $ - $ 27 $ - $ For the three-monthperiods endedSeptember30, 2024 2023 Forthenine-monthperiods ended September30,
Recognised in profit or loss		Recognised in other comprehensive income
- $ Forthe
2024			2023
Recognised in profit or loss	Recognised in other comprehensive income		Recognised in profit or loss	Recognised in other comprehensive income
- $	- $		27 $	- $

~23~

(9) SHORT-TERM BORROWINGS

SHORT-TERM BORROWINGS
Type ofborrowings Bank loans Unsecured loans Type of borrowings Bank loans Unsecured loans Type ofborrowings Bank loans Unsecured loans	September30,2024 Interestrate 35,704 $ 2.9%～3.0% December 31, 2023 Interest rate 32,137 $ 3.40%～3.50% September 30, 2023 Interest rate 58,292 $ 3.40%	Collateral None Collateral
		None Collateral
		None

Refer to Note 6(21), “ Finance costs” for interest expense recognised in profit or loss for the threemonth and nine-month periods ended September 30, 2024 and 2023.

(10) OTHER PAYABLES

OTHER PAYABLES
September 30, 2024 Accrued salaries and bonuses 96,100 $ Accrued employees’ compensation and directors’ remuneration 33,788 Payables on equipment 32,035 Others 179,995 341,918 $	December31,2023 100,306 $ 39,472 56,759 207,202 403,739 $	September30,2023
		98,056 $ 18,119 61,482 188,423
		366,080 $

(11) PENSIONS

A. The Company has set up a defined benefit pension plan in accordance with the Labor Standards Law, which applies to all regular employees’ service years prior to the enforcement of the Labor Pension Act (the “Act”) on July 1, 2005 and service years thereafter of employees who chose to continue to be covered under the pension scheme of the Labor Standards Law after the enforcement of the Act. In accordance with the Company's retirement plan, an employee may retire when the employee either (i) attains the age of 55 with 15 years of service, (ii) has more than 25 years of service, (iii) has reached the age of 65, or (iv) is incapacitated to work (compulsory retirement). The employees earn two units for each year of service for the first 15 years, and one unit for each additional year thereafter up to a maximum of 45 units. Any fraction of a year equal to or more than six months shall be counted as one year of service, and any fraction of a year less than six months shall be counted as half a year. According to the provisions, employees who retired due to their duties shall get additional 20%. Pension payments are based on the number of units earned and the average salary of the last six months prior to retirement. Calculation of average salary is in accordance with the Labor Standards Law of the R.O.C. The Company contributes monthly an amount equal to 2% of the employees' monthly salaries and

~24~

wages to the retirement fund deposited with Bank of Taiwan under the name of the independent retirement fund committee. Also, the Company would assess the balance in the aforementioned labor pension reserve account by December 31, every year. If the account balance is not enough to pay the pension calculated by the aforementioned method to the employees expected to qualify for retirement in the following year, the Company will make contribution for the deficit by end of March next year.

(a) The pension costs under the aforementioned defined benefit pension plan of the Company for the three-month and nine-month periods ended September 30, 2024 and 2023 were $272, $313, $817 and $938, respectively.
(b) The Company’s expected contributions to the pension plan for the year 2024 amounted to $2,830.
B. As a result of the enforcement of the Act, the Company set up a defined contribution pension plan which took effect on July 1, 2005. The local employees are eligible for the defined contribution plan. For employees who choose to be covered under the pension scheme of the Act, the Company contributes monthly an amount of not less than 6% of the employees’ monthly salaries and wages to the employees’ individual pension accounts at the Bureau of Labor Insurance. Pensions are paid by monthly installments or in lump sum based on the accumulated balances of the employees’ individual pension accounts. The subsidiaries in Mainland China (SciAnda (Changshu) Pharmaceuticals, Ltd., and SciAnda Shanghai Biochemical Technology, Ltd.) are subject to a government sponsored defined contribution plan. In accordance with the related Laws of the People’s Republic of China, the subsidiaries in Mainland China contribute monthly 18% of the employees’ monthly salaries and wages to an independent fund administered by the government. Other than the monthly contributions, these subsidiaries do not have further obligations. The other subsidiaries, SPT International, Ltd. and ScinoPharm Singapore Pte Ltd., had no employees. For the three-month and nine-month periods ended September 30, 2024 and 2023, the pension costs recognised under the aforementioned defined contribution pension plans were $10,410, $9,910, $31,047 and $29,377, respectively.

(12) SHARE CAPITAL

A. Movements in the number of the Company’s ordinary shares outstanding are as follows (in thousands of shares):

thousands of shares):
At January 1 and September 30	For the nine-monthperiods endedSeptember30,
	2024 790,739	2023
		790,739

B. As of September 30, 2024, the Company’s authorised capital was $10,000,000, and the paid-in capital was $7,907,392 (790,739 thousand shares) with a par value of $10 (in dollars) per share. All proceeds from shares issued have been collected.

~25~

(13) CAPITAL RESERVES

A. Pursuant to the R.O.C. Company Act, capital reserve arising from paid-in capital in excess of par value on issuance of common stocks and donations shall be exclusively used to cover accumulated deficit or, distribute cash or stocks in proportion to their share ownership, provided that the Company has no accumulated deficit. Further, the R.O.C. Securities and Exchange Act requires that the capital reserve to be capitalised mentioned above should not exceed 10% of the paid-in capital each year. Capital reserve should not be used to cover accumulated deficit unless the legal reserve is insufficient.
B. Movements on the Company’s capital reserve are as follows:

At January 1 Employee stock options forfeited - Company At September 30 At January 1 and September 30	Share premium Stock options Total 1,265,336 $ 29,353 $ 1,294,689 $ 482 482) ( - 1,265,818 $ 28,871 $ 1,294,689 $ Forthenine-monthperiod ended September30,2024 For the nine-month period ended September 30, 2023	Share premium Stock options Total 1,265,336 $ 29,353 $ 1,294,689 $ 482 482) ( - 1,265,818 $ 28,871 $ 1,294,689 $ Forthenine-monthperiod ended September30,2024 For the nine-month period ended September 30, 2023	Share premium Stock options Total 1,265,336 $ 29,353 $ 1,294,689 $ 482 482) ( - 1,265,818 $ 28,871 $ 1,294,689 $ Forthenine-monthperiod ended September30,2024 For the nine-month period ended September 30, 2023
	Share premium 1,256,454 $	Stock options 38,235 $	Total
			1,294,689 $

(14) SHARE-BASED PAYMENT – EMPLOYEES’ COMPENSATION

A. The Company issued 1 million units, 1.5 million units and 1.5 million units of employee stock options on December 3, 2013, November 6, 2015 and October 14, 2016, respectively (the ‘Grant Date’). The exercise price of the options was set at $91.70 (in dollars), $41.65 (in dollars) and $40.55 (in dollars), respectively, which was based on the closing market price of the Company's common shares on the Grant Dates. Each option gives the holder the right to purchase one share of the Company's common stocks. The exercise price is subject to further adjustments when there is a change in the number of shares of the Company's common stocks, the cash dividend of the common stocks is more than 1.5% of the current price per share or there is a decrease in common stocks caused by capital reduction not due to the retirement of treasury share after the Grant Date. Contract period of the employee stock option plans is 10 years, and options are exercisable in 2 years after the Grant Date.

~26~

B. Details of the share-based payment arrangements are as follows:

	Forthenine-monthperiod	ended September30,2024	ended September30,2024
			Weighted-average
	Number of options		exercise price
	(in thousand units)		(in dollars)
Options outstanding at beginning of the period	1,164	$	36.07
Options forfeited	36) (		36.13
Options outstanding at end of the period	1,128		36.07
Options exercisable at end of the period	1,128		36.07
	For the nine-month period	ended September 30, 2023
			Weighted-average
	Number of options		exercise price
	(in thousand units)		(in dollars)
Options outstanding at beginning and end of the period	1,526	$	43.50
Options exercisable at end of the period	1,526		43.50

C. The expiry date, exercisable shares and exercise prices of the employee stock options at balance sheet date are as follows:

		September30,	September30,	2024	December31,	December31,	2023
			Exercise price			Exercise price
		No. of stocks	(in dollars)		No. of stocks		(in dollars)
Grant date	Expiry date	(unitinthousands)		(Note)	(unitinthousands)		(Note)
11.6.2015	11.5.2025	515	$	35.80	527	$	35.80
10.14.2016	10.13.2026	613		36.30	637		36.30
					September30,		2023
						Exercise price
					No. of stocks		(in dollars)
Grant date	Expiry date				(unitinthousands)		(Note)
12.3.2013	12.2.2023				319	$	71.60
11.6.2015	11.5.2025				539		35.80
10.14.2016	10.13.2026				668		36.30
Note: Exercise	price is adjusted according to a specific formula.

~27~

D. The fair value of the Group’s employee stock options on Grant Date was evaluated using the combination of Hull & White and the Ritchken trinomial option valuation model. Related information is as follows:

Stock Type of price arrangement Grant date (in dollars) Employee 12.3.2013 91.70 $ stock options Employee 11.6.2015 41.65 stock options Employee 10.14.2016 40.55 stock options	Exercise price Price Option (in dollars) volatility life 91.70 $ 28.50% 10 years (Note) 41.65 37.63% 10 years (Note) 40.55 37.20% 10 years (Note)	Fair value Expected Interest per unit dividends rate (in dollars) 1.5% 1.7145% 26.045 $ 1.5% 1.2936% 13.799 1.5% 0.9223% 13.171

Note: According to daily returns of the Company's stock for the previous year, the annualized volatility were 28.50%, 37.63% and 37.20%, respectively.

(15) RETAINED EARNINGS

A. Pursuant to the amended R.O.C. Company Act, the current year's after-tax earnings should be used initially to cover any accumulated deficit; thereafter 10% of the remaining earnings should be set aside as legal reserve until the balance of legal reserve is equal to that of paid-in capital. The legal reserve shall be exclusively used to cover accumulated deficit, to issue new stocks, or to distribute cash to shareholders in proportion to their share ownership. The use of legal reserve for the issuance of stocks or cash dividends to shareholders in proportion to their share ownership is permitted provided that the distribution of the reserve is limited to the portion in excess of 25% of the Company’s paid-in capital.
B. According to the Articles of Incorporation of the Company, since the Company is in a changeable industry environment and the life cycle of the Company is in a stable growth, the appropriation of earnings should consider fund requirements and capital budget to decide how much earnings will be kept or distributed and how much cash dividends will be distributed. According to the Company’s Articles of Incorporation, 10% of the annual net income, except for offsetting any loss of prior years and paying all taxes and dues according to laws, after adding items other than net profit after taxes for the year into undistributed surplus earnings of current year, 10% of the remaining shall be set aside as legal reserve. The remaining net income and the unappropriated retained earnings from prior years can be distributed in accordance with a resolution passed during a meeting of the Board of Directors and approved at the stockholders' meeting. Of the amount to be distributed by the Company, stockholders’ dividends shall comprise 50% to 100% of the unappropriated retained earnings, and the percentage of cash dividends shall not be less than 30% of dividends distributed.

~28~

C. In accordance with the regulations, the Company shall set aside special reserve from the debit balance on other equity items at the balance sheet date before distributing earnings. When debit balance on other equity items is reversed subsequently, the reversed amount could be included in the distributable earnings. The amounts previously set aside by the Company as special reserve on initial application of IFRSs in accordance with Order No. Jin-Guan-Zheng-Fa-Zi Letter No. 1010012865, dated April 6, 2012, shall be reversed proportionately when the relevant assets are used, disposed of or reclassified subsequently. As of September 30, 2024, the amount of special reserve on initial application of IFRSs provided in accordance with the order from Financial Supervisory Committee was $22,829.
D. The Company recognised cash dividends distributed to owners amounting to $284,666 ($0.36 (in dollars) per share) for the year ended December 31, 2023. On May 28, 2024, the Company’s stockholders approved the distribution of cash dividends of $237,222 ($0.3 (in dollars) per share) from 2023 earnings.

(16) OTHER EQUITY ITEMS

from 2023 earnings. OTHER EQUITY ITEMS
			For the nine-month		period endedSeptember		30,2024
					Unrealised loss
		Currencytranslation			onvaluation		Total
At January 1	($		88,156)	($	97,700)	($	185,856)
Revaluation			-		4,591		4,591
Currency translation differences
- Group			66,099		-		66,099
At September 30	($		22,057)	($	93,109)	($	115,166)
			For the nine-monthperiod endedSeptember				30,2023
					Unrealised loss
		Currencytranslation			onvaluation		Total
At January 1	($		43,119)	($	55,057)	($	98,176)
Revaluation			-	(	42,252)	(	42,252)
Currency translation differences
- Group	(		10,431)		-	(	10,431)
At September 30	($		53,550)	($	97,309)	($	150,859)

~29~

(17) OPERATING REVENUE

A. Disaggregation of revenue from contracts with customers

The Group derives revenue from the transfer of goods at a point in time and the rendering of services over time in the following major product lines:

For the three-month period ended September 30, 2024 Timing of revenue recognition: At a point in time Over time For the three-month period ended September30,2023 Timing of revenue recognition: At a point in time Over time For the nine-month period ended September30,2024 Timing of revenue recognition: At a point in time Over time For the nine-month period ended September30,2023 Timing of revenue recognition: At a point in time Over time	API Income 577,488 $ - 577,488 $ API Income 589,850 $ - 589,850 $ API Income 2,087,535 $ - 2,087,535 $ API Income 1,911,906 $ - 1,911,906 $	Injection Product Income 20,512 $ - 20,512 $ Injection Product Income 40,084 $ - 40,084 $ Injection Product Income 58,991 $ - 58,991 $ Injection Product Income 40,084 $ - 40,084 $	Technical Service Income - $ 126,174 126,174 $ Technical Service Income - $ 23,953 23,953 $ Technical Service Income - $ 188,114 188,114 $ Technical Service Income - $ 95,268 95,268 $	Other Operating Income 49 $ - 49 $ Other Operating Income 5,701 $ - 5,701 $ Other Operating Income 35,168 $ - 35,168 $ Other Operating Income 15,661 $ - 15,661 $	Total
					598,049 $ 126,174
					724,223 $
					Total
					635,635 $ 23,953
					659,588 $
					Total
					2,181,694 $ 188,114
					2,369,808 $
					Total
					1,967,651 $ 95,268
					2,062,919 $

~30~

B. The Group has recognised contract liabilities related to the contract revenue from advance customer payment of $157,755, $110,967, $90,617 and $67,752 as of September 30, 2024, December 31, 2023, September 30, 2023 and January 1, 2023, respectively.
C. The revenue recognised that was included in the contract liability balance at the beginning of the period amounted to $6,393, $19,635, $64,416 and $31,845 for the three-month and nine-month periods ended September 30, 2024 and 2023, respectively.

(18) INTEREST INCOME

Interest income from bank deposits

For the three-month periods ended September 30, 2024 2023 $ 15,064 $ 13,198 For the nine-month periods ended September 30, 2024 2023 $ 45,238 $ 39,817

(19) OTHER INCOME

Government grants income Others

Government grants income Income from counterparty default Others

For	the three-monthperiods ended	the three-monthperiods ended	September30,
	2024		2023
$	2,078	$	1,068
	298		598
$	2,376	$	1,666
For	the nine-month periods	ended	September 30,
	2024		2023
$	2,078	$	1,068
	-		1,970
	2,368		7,155
$	4,446	$	10,193

(20) OTHER GAINS AND LOSSES

Net currency exchange (loss) gain Gain on reversal of impairment loss Net gain (loss) on financial assets/liabilities at fair value through profit or loss Loss on disposal of property, plant and equipment Others

For	the three-monthperiods ended	the three-monthperiods ended	the three-monthperiods ended	September30,
	2024			2023
($	10,958)		$	11,313
	-			27
	1,506	(		11,265)
(	3,588)	(		58)
(	365)	(		1,044)
($	13,405)	($		1,027)

~31~

For the nine-month periods ended September 30,

			2024			2023
Net currency exchange gain		$	28,626		$	14,444
Gain on reversal of impairment loss			-			27
Net loss on financial assets/liabilities at
fair value through profit or loss	(		21,178)	(		18,967)
Loss on disposal of property, plant
and equipment	(		4,278)	(		386)
Others	(		2,448)	(		3,075)
		$	722	($		7,957)

(21) FINANCE COSTS

For the three-month periods ended September 30,

		For the three-month periods ended September 30,	For the three-month periods ended September 30,	s ended September 30,	s ended September 30,
EXPENSES BY NATURE Interest expense: Bank loans Interest on lease liabilities Interest expense: Bank loans Interest on lease liabilities Employee benefit expenses Depreciation of property, plant and equipment Depreciation of right-of-use assets Amortisation Employee benefit expenses Depreciation of property, plant and equipment Depreciation of right-of-use assets Amortisation	Forthe	2024 2023 119 $ 568 $ 1,815 1,676 1,934 $ 2,244 $ For the nine-month periods ended September 30,		2023 568 $ 1,676
				2,244 $
		2024 2023 528 $ 2,003 $ 5,473 5,052 6,001 $ 7,055 $ three-monthperiod ended September30,2024		2023
				2,003 $ 5,052
				7,055 $
	Operating costs Operating expenses Total 166,166 $ 78,635 $ 244,801 $ 99,085 18,042 117,127 - 4,315 4,315 680 1,799 2,479 Forthe three-monthperiod ended September30,2023				Total
	Operating costs 159,193 $ 90,869 - 589		Operating expenses 81,705 $ 16,872 3,957 1,192		Total
					240,898 $ 107,741 3,957 1,781

(22) EXPENSES BY NATURE

~32~

Operating costs Operating expenses Total 499,039 $ 253,946 $ 752,985 $ 293,108 51,893 345,001 - 12,928 12,928 2,062 4,814 6,876 Operating costs Operating expenses Total 460,718 $ 240,807 $ 701,525 $ 276,769 50,544 327,313 - 11,878 11,878 1,872 2,880 4,752 Forthenine-monthperiod ended September30,2024 For the nine-monthperiod endedSeptember30,2023 Forthe three-monthperiod ended September30,2024	Operating costs Operating expenses Total 499,039 $ 253,946 $ 752,985 $ 293,108 51,893 345,001 - 12,928 12,928 2,062 4,814 6,876 Operating costs Operating expenses Total 460,718 $ 240,807 $ 701,525 $ 276,769 50,544 327,313 - 11,878 11,878 1,872 2,880 4,752 Forthenine-monthperiod ended September30,2024 For the nine-monthperiod endedSeptember30,2023 Forthe three-monthperiod ended September30,2024	Operating costs Operating expenses Total 499,039 $ 253,946 $ 752,985 $ 293,108 51,893 345,001 - 12,928 12,928 2,062 4,814 6,876 Operating costs Operating expenses Total 460,718 $ 240,807 $ 701,525 $ 276,769 50,544 327,313 - 11,878 11,878 1,872 2,880 4,752 Forthenine-monthperiod ended September30,2024 For the nine-monthperiod endedSeptember30,2023 Forthe three-monthperiod ended September30,2024
Operating costs Operating expenses Total 140,373 $ 65,268 $ 205,641 $ 11,617 5,066 16,683 7,382 3,300 10,682 6,794 5,001 11,795 166,166 $ 78,635 $ 244,801 $ Forthe three-monthperiod ended September30,2023		Total
		205,641 $ 16,683 10,682 11,795
		244,801 $
Operating costs Operating expenses Total 135,047 $ 68,811 $ 203,858 $ 11,176 4,892 16,068 7,081 3,142 10,223 5,889 4,860 10,749 159,193 $ 81,705 $ 240,898 $ Forthenine-monthperiod ended September30,2024		Total
		203,858 $ 16,068 10,223 10,749
		240,898 $
Operating costs 420,602 $ 36,256 22,532 19,649 499,039 $	Operating expenses 213,705 $ 16,302 9,332 14,607 253,946 $	Total
		634,307 $ 52,558 31,864 34,256
		752,985 $

~33~

Salaries and wages Labor and health insurance expenses Pension costs Other personnel expenses	Operating costs Operating expenses Total 389,154 $ 203,365 $ 592,519 $ 33,409 15,103 48,512 21,206 9,109 30,315 16,949 13,230 30,179 460,718 $ 240,807 $ 701,525 $ Forthenine-monthperiod ended September30,2023

A. According to the Articles of Incorporation of the Company, a ratio of distributable profit of the current year, after covering accumulated losses, shall be distributed as employees’ compensation and directors’ remuneration. The ratio shall not be lower than 2% for employees’ compensation and shall not be higher than 2% for directors’ remuneration.
B. For the three-month and nine-month periods ended September 30, 2024 and 2023, the employees’ compensation was accrued at $3,392, $3,906, $29,916 and $15,785, respectively, while the directors’ remuneration was accrued at $433, $553, $3,872 and $2,334, respectively. The aforementioned amounts were recognised in salary expenses and were estimated and accrued based on the earnings of current period and the percentage specified in the Articles of Incorporation of the Company. The actual amount approved at the Board of Directors’ meeting for employees’ compensation and directors’ remuneration for 2023 was $39,472, which was the same as the amount estimated in the 2023 financial statements. The employees’ compensation was distributed in the form of cash for 2023. Information about the appropriation of employees’ compensation and directors’ remuneration by the Company as resolved by the Board of Directors will be posted in the “Market Observation Post System” at the website of the Taiwan Stock Exchange.

(24) INCOME TAX

A. Income tax expense

Components of income tax expense:

Exchange. COME TAX Income tax expense Components of income tax expense:
		Forthe three-monthperiods ended September30,
			2024		2023
Current income tax:
Income tax for the period		$	12,814	$	1,579
Deferred income tax:
Origination and reversal of temporary
differences	(		5,980)		6,770
Income tax expense		$	6,834	$	8,349

~34~

		Forthenine-monthperiods ended September30,	Forthenine-monthperiods ended September30,	Forthenine-monthperiods ended September30,	Forthenine-monthperiods ended September30,	Forthenine-monthperiods ended September30,
			2024			2023
Current income tax:
Income tax for the period		$	58,035		$	26,183
Over provision of prior year's
income tax	(		2,967)	(		4,694)
Total current tax			55,068			21,489
Deferred income tax:
Origination and reversal of temporary
differences			2,149			6,719
Income tax expense		$	57,217		$	28,208

B. The Company’s income tax returns through 2022 have been assessed and approved by the Tax Authority, and there were no disputes existing between the Company and the Authority as of November 4, 2024.

(25) EARNINGS PER SHARE (“EPS”)

November 4, 2024. EARNINGS PER SHARE (“EPS”)
Basic earnings per share Profit attributable to ordinary stockholders of the parent Diluted earnings per share Profit attributable to ordinary stockholders of the parent Assumed conversion of all dilutive potential ordinary shares Employees’ stock options Employees’ compensation Profit attributable to ordinary stockholders of the parent plus assumed conversion of all dilutive potential ordinary shares	Forthe three-monthperiod ended September		30,2024
	Amount aftertax 27,103 $ 27,103 $ - - 27,103 $	Weighted average number of shares outstanding (sharesinthousands) 790,739 790,739 - 1,178 791,917	EPS (indollars)
			0.03 $
			0.03 $

~35~

Weighted average number of shares outstanding Amount aftertax (sharesinthousands) 30,719 $ 790,739 30,719 $ 790,739 - - - 580 30,719 $ 791,319 For the three-monthperiod endedSeptember Forthenine-monthperiod ended September	Weighted average number of shares outstanding Amount aftertax (sharesinthousands) 30,719 $ 790,739 30,719 $ 790,739 - - - 580 30,719 $ 791,319 For the three-monthperiod endedSeptember Forthenine-monthperiod ended September	EPS (indollars) 30,2023
		0.04 $
		0.04 $
		30,2024
Amount aftertax 242,008 $ 242,008 $ - - 242,008 $	Weighted average number of shares outstanding (sharesinthousands) 790,739 790,739 - 1,471 792,210	EPS (indollars)
		0.31 $
		0.31 $

~36~

Basic earnings per share Profit attributable to ordinary stockholders of the parent Diluted earnings per share Profit attributable to ordinary stockholders of the parent Assumed conversion of all dilutive potential ordinary shares Employees’ stock options Employees’ compensation Profit attributable to ordinary stockholders of the parent plus assumed conversion of all dilutive potential ordinary shares	Weighted average number of shares outstanding Amount aftertax (sharesinthousands) 129,678 $ 790,739 129,678 $ 790,739 - - - 918 129,678 $ 791,657 For the nine-monthperiod endedSeptember	EPS (indollars) 30,2023
		0.16 $
		0.16 $

For the three-month and nine-month periods ended September 30, 2024 and 2023, some abovementioned stock options issued were anti-dilutive; therefore they were not included in the diluted EPS calculation.

(26) SUPPLEMENTAL CASH FLOW INFORMATION

A. Investing activities with partial cash payments:

Investing activities with partial cash payments:
		Forthenine-monthperiods ended September30,
			2024		2023
Purchase of property, plant and equipment		$	46,130	$	62,451
Add: Beginning balance of payable
on equipment (listed as “Other payables”)			56,759		53,975
Less: Ending balance of payable
on equipment (listed as “Other payables”)	(		14,214)	(	61,482)
Cash paid for acquisition of property, plant
and equipment		$	88,675	$	54,944
		For the nine-monthperiods endedSeptember30,
			2024		2023
Purchase of prepayments for equipment		$	159,800	$	-
Less: Ending balance of payable
on equipment (listed as “Other payables”)	(		17,821)		-
Cash paid for prepayments for equipment		$	141,979	$	-

~37~

B. Investing activities with no cash flow effects:

==> picture [482 x 404] intentionally omitted <==

----- Start of picture text -----

For the nine-month periods ended September 30,
2024 2023
Prepayments for equipment reclassified to
$ 201,670 $ 82,192
property, plant and equipment
CHANGES IN LIABILITIES FROM FINANCING ACTIVITIES
Guarantee Liabilities from
For the nine-month period ended Short-term Lease deposits financing
September 30, 2024 borrowings liabilities received activities-gross
At January 1, 2024 $ 32,137 $ 587,787 $ 1,297 $ 621,221
Changes in cash flow from
financing activities 2,166 ( 9,350) 2,974 ( 4,210)
Impact of changes in
foreign exchange rate 1,401 - 72 1,473
Changes in other
non-cash items - 61,985 - 61,985
At September 30, 2024 $ 35,704 $ 640,422 $ 4,343 $ 680,469
Guarantee Liabilities from
For the nine-month period ended Short-term Lease deposits financing
September 30, 2023 borrowings liabilities received activities-gross
At January 1, 2023 $ 77,599 $ 599,074 $ 2,357 $ 679,030
Changes in cash flow from
financing activities ( 18,674) ( 8,453) ( 1,466) ( 28,593)
Impact of changes in
foreign exchange rate ( 633) - ( 7) ( 640)
At September 30, 2023 $ 58,292 $ 590,621 $ 884 $ 649,797
----- End of picture text -----

(27) CHANGES IN LIABILITIES FROM FINANCING ACTIVITIES

7. RELATED PARTY TRANSACTIONS

(1) Parent and ultimate controlling party

The ultimate parent and ultimate controlling party of the Company is Uni-President Enterprises Corp.

(2) Names of related parties and relationship

Names of related parties

Uni-President Enterprises Corp. President Securities Corp. President Transnet Corp. President Tokyo Corp. Mech-President Corp. President Chain Store Corp. President Chain Store Tokyo Marketing Corp. President Information Corp. Duskin Serve Taiwan Co., Ltd.

Uni-President Enterprises (China) Investment Corp. Uni-President Shanghai Pearly Century Co., Ltd.

Relationship with the Company

Ultimate parent company

Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company

~38~

(3) Significant transactions and balances with related parties

1.Transaction of assets

ransaction of assets
	For the nine-month periods ended September 30,
	2024	2023
Acquisition of property, plant
and equipment
`－`Associate of ultimate parent company	1,017 $	- $

For the three-month periods ended September 30, 2024 and 2023, there was no acquisition of property, plant and equipment.

2.Other expenses

property, plant and equipment. Other expenses
Management service fees: `－`Ultimate parent company `－`Associate of ultimate parent company	Forthe three-monthperiods ended September30,
	2024 51 $ 764 815 $	2023
		2,190 $ 662
		2,852 $

Management service fees: － Ultimate parent company － Associate of ultimate parent company

51 $ 2,190 $ 764 662 815 $ 2,852 $	51 $ 2,190 $ 764 662 815 $ 2,852 $
For the nine-month periods ended September 30,
2024 1,963 $ 2,285 4,248 $	2023
	2,357 $ 2,374
	4,731 $

(4) Key management compensation

Salaries and other short-term employee benefits Post-employment benefits Termination benefits Salaries and other short-term employee benefits Post-employment benefits Termination benefits	Forthe three-monthperiods ended September30,	Forthe three-monthperiods ended September30,
	2024 2023 11,344 $ 11,884 $ 121 160 400 398 11,865 $ 12,442 $ For the nine-monthperiods endedSeptember30,	2023
		11,884 $ 160 398
		12,442 $
	2024 40,176 $ 435 1,196 41,807 $	2023
		35,816 $ 480 1,143
		37,439 $

~39~

8. PLEDGED ASSETS

Details of the Group’s assets pledged as collateral are as follows:

Assets September 30, 2024 December 31, 2023 September 30, 2023 Purpose of collateral Pledged time deposits (Note) $ 30,940 $ 30,940 $ 30,940 Performance guarantee, customs duty and guarantee for credit card

Note : Listed as “Other financial assets - non-current”.

9. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNISED CONTRACT

COMMITMENTS

(1) As of September 30, 2024, December 31, 2023, and September 30, 2023, the Group’s unused letters — —
of credit amounted to $ , $4,597 and $ , respectively.
(2) As of September 30, 2024, December 31, 2023, and September 30, 2023, the Group’s remaining balance due for construction in progress and prepayments for equipment was $97,955, $15,258 and $21,068, respectively.
(3) The amounts of endorsements and guarantees for subsidiaries were as follows:

Nature September 30, 2024 December 31, 2023 September 30, 2023 SciAnda (Changshu) Guarantee for Pharmaceuticals, Ltd. financing amount $ 180,375 $ 302,725 $ 309,523

As of September 30, 2024, December 31, 2023, and September 30, 2023, the actual amount drawn down for endorsements and guarantees to subsidiaries was $ － .

10. SIGNIFICANT DISASTER LOSS: None.

11. SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE: None.

12. OTHERS

(1) Capital management

The Group’s objectives on managing capital are to safeguard the Group’s ability to continue as a going concern in order to provide returns for shareholders, to maintain an optimal capital structure, to reduce the cost of capital and to maintain an adequate capital structure to enable the expansion and enhancement of equipment. In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return of capital to shareholders, and issue new shares or sell assets to reduce debts.

(2) Financial instruments

A. Financial instruments

For details of the Group’s financial instruments by category, refer to Note 6.

B. Risk management policies
(a) The Group’s activities expose it to a variety of financial risks: market risk (including foreign exchange risk, price risk and interest rate risk), credit risk and liquidity risk.
(b) The Group’s treasury identifies, evaluates and hedges financial risks closely with the Group’s operating units. The Board provides written principles for overall risk management, as well as written policies covering specific areas and matters, such as use of derivative financial

~40~

instruments and investment of excess liquidity.

(c) Information about derivative financial instruments that are used to hedge financial risk are provided in Note 6(2), “Financial assets and liabilities at fair value through profit or loss”.
C. Significant financial risks and degrees of financial risks
(a) Market risk
- I. Foreign exchange rate risk
- (i) The Group operates internationally and is exposed to foreign exchange risk arising from the transactions of the Company and its subsidiaries used in various functional currency, primarily with respect to USD. Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities.
- (ii) To manage their foreign exchange risk arising from future commercial transactions and recognised assets and liabilities, entities in the Group are required to hedge their foreign exchange risk exposure using forward foreign exchange contracts. However, the Group does not adopt hedging accounting. Details of financial assets or liabilities at fair value through profit or loss are provided in Note 6(2), “Financial assets and liabilities at fair value through profit or loss”.
- (iii)The Group’s businesses involve some non-functional currency operations (the Company’s and certain subsidiaries’ functional currency: NTD; other subsidiaries’ functional currency: CNY). The information on assets and liabilities denominated in foreign currencies whose values would be materially affected by the exchange rate fluctuations is as follows:

fluctuations is as follows:
(Foreign currency: functional currency) Financial assets Monetary items USD:NTD USD:CNY Financial liabilities Monetary items USD:NTD EUR:NTD	September30,2024
	Foreign currency amount (inthousands) 16,303 $ 319 571 104	Exchangerate 31.65 7.019 31.65 35.38	Book value (NTD)
			515,990 $ 10,096 18,072 3,680

~41~

(iv)As of September 30, 2024 and 2023, if the NTD:USD exchange rate appreciates/depreciates by 5% with all other factors remaining constant, the Group’s net profit after tax for the nine-month periods ended September 30, 2024 and 2023 would increase/decrease by $19,917 and $14,698, respectively. If the exchange rate of NTD to other currencies had appreciated/depreciated by 5% with all other factors remaining constant, the effect on the Group’s net profit after tax for the nine-month periods ended September 30, 2024 and 2023 is immaterial. Foreign currency amount (inthousands) Exchangerate Book value (NTD) (Foreign currency: functional currency) Financial assets Monetary items USD:NTD 25,330 $ 30.71 777,884 $ CNY:NTD 8,780 4.325 37,974 Financial liabilities Monetary items USD:NTD 712 30.71 21,866 CHF:NTD 132 36.49 4,817 Foreign currency amount (inthousands) Exchangerate Book value (NTD) (Foreign currency: functional currency) Financial assets Monetary items USD:NTD 11,554 $ 32.27 372,848 $ CNY:NTD 1,140 4.422 5,041 Financial liabilities Monetary items USD:NTD 167 32.27 5,389 CNY:NTD 875 4.422 3,869 EUR:NTD 72 33.91 2,442 CHF:NTD 48 33.28 1,597 September30,2023 December31,2023	December31,2023
	Foreign currency amount (inthousands) Exchangerate 25,330 $ 30.71 8,780 4.325 712 30.71 132 36.49 September30,2023	Book value (NTD)
		777,884 $ 37,974 21,866 4,817
		Book value (NTD)

(v)Total exchange (loss) gain including realised and unrealised arising from significant foreign exchange variation on the monetary items held by the Group for the three-month and nine-month periods ended September 30, 2024 and 2023 amounted to ($10,958), $11,313, $28,626 and $14,444 respectively.

~42~

II. Price risk

The Group’s equity securities, which are exposed to price risk, are the held financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income. To manage its price risk arising from investments in equity securities, the Group diversifies its portfolio and set stop-loss amounts for these instruments. The Group expects no significant market risk.

III. Cash flow and fair value interest rate risk

(i) The Group’s main interest rate risk arises from short-term borrowings with variable rates and exposes the Group to cash flow interest rate risk. During the nine-month periods ended September 30, 2024 and 2023, the Group’s borrowings at variable rate were denominated in CNY.
(ii) The Group’s borrowings are measured at amortised cost. The borrowings are periodically contractually repriced and to that extent are also exposed to the risk of future changes in market interest rates.
(iii) If the borrowing interest rates had increased/decreased by 10% with all other variables held constant, the effect on post-tax profit for the nine-month periods ended September 30, 2024 and 2023 is immaterial.

(b) Credit risk

I. Credit risk refers to the risk of financial loss to the Group arising from default by the clients or counterparties of financial instruments on the contract obligations. The main factor is that counterparties could not repay in full the accounts receivable based on the agreed terms.
II. The Group manages its credit risk taking into consideration the entire group’s concern. For banks and financial institutions, only independently rated parties with a minimum rating of 'A' are accepted. According to the Group’s credit policy, each local entity in the Group is responsible for managing and analysing the credit risk for each of their new clients before standard payment and delivery terms and conditions are offered. Internal risk control assesses the credit quality of the customers, taking into account their financial position, past experience and other factors. Individual risk limits are set based on internal or external ratings in accordance with limits set by the Board of Directors. The utilisation of credit limits is regularly monitored.
III. The Group adopts the following assumption under IFRS 9: If the contract payments were past due over 30 days based on the terms, there has been a significant increase in credit risk on that instrument since initial recognition.
IV. The Group manages its credit risk, whereby if the contract payments are past due over 180 days based on the terms, there has been impairment.

~43~

V. The Group classifies customers’ accounts receivable in accordance with the credit rating of the customer and credit risk on trade. The Group applies the simplified approach using the provision matrix to estimate expected credit loss, and use the forecastability to adjust historical and timely information to assess the default possibility of accounts receivable. Movements in relation to the Group applying the simplified approach to provide loss allowance for accounts receivable are as follows:

At January 1 Expected credit loss Impact of foreign exchange rate At September 30	2024 2023 231 $ 303 $ 1,681 1,531 5 8 1,917 $ 1,842 $ For the nine-monthperiods endedSeptember30,

(c) Liquidity risk

I. Cash flow forecasting is performed by the Group’s treasury department which monitors rolling forecasts of the Group’s liquidity requirements to ensure it has sufficient cash to meet operational needs while maintaining sufficient headroom on its undrawn committed borrowing facilities at all times so that the Group does not breach borrowing limits or covenants (where applicable) on any of its borrowing facilities.
II. The Group has undrawn borrowing facilities amounting to $5,067,660, $4,755,797 and $5,138,532 as of September 30, 2024, December 31, 2023, and September 30, 2023, respectively.
III. The following table comprises the Group’s non-derivative financial liabilities and derivative financial liabilities with gross-amount settlement that are grouped by their maturity. Non-derivative financial liabilities are analysed from the balance sheet date to the contract maturity date, and derivative financial liabilities are analysed from the balance sheet date to the expected maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

September30,2024 Short-term borrowings Notes payable Accounts payable Other payables Lease liabilities Guarantee deposits received Non-derivative financial liabilities:	Less than 1year 36,581 $ 1,603 126,966 341,918 18,398 -	Between 1 and2years - $ - - - 18,398 4,343	Between 2 and 5 years - $ - - - 55,195 -	More than 5 years
				- $ - - - 722,128 -

~44~

December31,2023 Short-term borrowings Notes payable Accounts payable Other payables Lease liabilities Guarantee deposits received September30,2023 Short-term borrowings Notes payable Accounts payable Other payables Lease liabilities Guarantee deposits received Derivative financial liabilities: Forward exchange contracts Non-derivative financial liabilities: Non-derivative financial liabilities:	Less than 1year 32,547 $ 1,179 101,278 403,739 17,664 - Less than 1year 59,157 $ 1,553 140,792 366,080 18,006 - 1,271	Between 1 and2years - $ - - - 16,640 1,297 Between 1 and2years - $ - - - 16,640 884 -	Between 2 and 5 years - $ - - - 49,921 - Between 2 and 5 years - $ - - - 49,921 - -	More than 5 years
				- $ - - - 665,614 - More than 5 years
				- $ - - - 669,774 - -

(3) Fair value information

A. The different levels that the inputs to valuation techniques are used to measure fair value of financial and non-financial instruments have been defined as follows:
Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. A market is regarded as active where a market in which transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. The fair value of the Group’s investment in foreign exchange contracts is included in Level 2.
Level 3: Unobservable inputs for the asset or liability. The fair value of the Group’s investment in equity investment without active market is included in Level 3.
B. Financial instruments not measured at fair value
The carrying amounts of cash and cash equivalents, accounts receivable, other receivables, guarantee deposits paid, other financial assets - non-current, short-term borrowings, notes payable, accounts payable, other payables and guarantee deposits received are approximate to their fair values.

~45~

C. The related information on financial instruments measured at fair value by level on the basis of the nature, characteristics and risks of the assets and liabilities are as follows:

September30,2024 Assets: Recurring fair value measurements Financial assets at fair value through profit or loss Derivative instruments Financial assets at fair value through other comprehensive income Equity securities December31,2023 Assets: Recurring fair value measurements Financial assets at fair value through profit or loss Derivative instruments Financial assets at fair value through other comprehensive income Equity securities September30,2023 Assets: Recurring fair value measurements Financial assets at fair value through other comprehensive income Equity securities Liabilities: Recurring fair value measurements Financial liabilities at fair value through profit or loss Derivative instruments	Level 1 - $ - $ Level 1 - $ - $ Level 1 - $ - $	Level 2 1,974 $ - $ Level 2 8,304 $ - $ Level 2 - $ 1,271 $	Level3 - $ 74,564 $ Level3 - $ 69,973 $ Level3 70,364 $ - $	Total
				1,974 $
				74,564 $
				Total
				8,304 $
				69,973 $
				Total
				70,364 $
				1,271 $

D. The methods and assumptions the Group used to measure fair value are as follows:

(a) The fair value of other financial instruments is measured by using valuation techniques or by reference to counterparty quotes. The fair value of financial instruments measured by using valuation techniques can be referred to current fair value of instruments with similar terms and characteristics in substance, discounted cash flow method or other valuation methods, including calculated by applying model using market information available at the consolidated balance sheet date.

~46~

(b) When assessing non-standard and low-complexity financial instruments, for example, debt instruments without active market, interest rate swap contracts, foreign exchange swap contracts and options, the Group adopts valuation technique that is widely used by market participants. The inputs used in the valuation method to measure these financial instruments are normally observable in the market.
(c) Forward foreign exchange contracts are usually valued based on the current forward exchange rate.
E. For the nine-month periods ended September 30, 2024 and 2023, there was no transfer between Level 1 and Level 2.
F. The following chart is the movement of Level 3 for the nine-month periods ended September 30, 2024 and 2023:

At January 1 Gain (loss) recognised in other comprehensive loss At September 30	2024 2023 Equity instrument Equityinstrument 69,973 $ 112,616 $ 4,591 42,252) ( 74,564 $ 70,364 $ For the nine-month periods ended September 30,

G. For the nine-month periods ended September 30, 2024 and 2023, there was no transfer in (out) Level 3.
H. The Group’s valuation procedures for fair value measurements is categorised within Level 3, which is to verify independent fair value of financial instruments. Such assessment is to ensure the valuation results are reasonable by applying independent information to make results close to current market conditions, confirming the resource of information is independent, reliable and in line with other resources and represented as the exercisable price, and frequently assess to make any other necessary adjustments to the fair value.

~47~

I. The following is the qualitative information of significant unobservable inputs and sensitivity analysis of changes in significant unobservable inputs to valuation model used in Level 3 fair value measurement:

Valuation technique	Significant unobservable input	Range (weighted average)	Relationship of inputs to fairvalue
Net asset value Valuation technique	Discount for lack of marketability Significant unobservable input	50% Range (weighted average)	The higher the discount for lack of marketability, the lower the fair value Relationship of inputs to fairvalue
Net asset value Valuation technique	Discount for lack of marketability Significant unobservable input	50% Range (weighted average)	The higher the discount for lack of marketability, the lower the fair value Relationship of inputs to fairvalue
Net asset value	Discount for lack of marketability	50%	The higher the discount for lack of marketability, the lower the fair value

J. The Group has carefully assessed the valuation models and assumptions used to measure fair value. However, use of different valuation models or assumptions may result in different measurement. If the discount for lack of marketability increased or decreased by 1% for Level 3, the effect on other comprehensive income for the nine-month periods ended September 30, 2024 and 2023 is immaterial.

~48~

13. SUPPLEMENTARY DISCLOSURES

According to the current regulatory requirements, the Group is only required to disclose the information for the nine-month period ended September 30, 2024.

(1) Significant transactions information

A. Loans to others: None.
B. Provision of endorsements and guarantees to others: Refer to table 1.
C. Holding of marketable securities at the end of the period (not including subsidiaries, associates and joint ventures): Refer to table 2.
D. Acquisition or sale of the same security with the accumulated cost exceeding $300 million or 20% of the Company’s paid-in capital: None.
E. Acquisition of real estate reaching $300 million or 20% of paid-in capital or more: None.
F. Disposal of real estate reaching $300 million or 20% of paid-in capital or more: None.
G. Purchases or sales of goods from or to related parties reaching $100 million or 20% of paid-in capital or more: Refer to table 3.
H. Receivables from related parties reaching $100 million or 20% of paid-in capital or more: None.
I. Trading in derivative instruments undertaken during the reporting periods: Refer to Note 6(2), “Financial assets and liabilities at fair value through profit or loss”.
J. Significant inter-company transactions during the reporting periods: Refer to table 4.

(2) Information on investees

Names, locations and other information of investee companies (not including investees in Mainland China): Refer to table 5.

(3) Information on investments in Mainland China

A. Basic information: Refer to table 6.
B. Significant transactions, either directly or indirectly through a third area, with investee companies in the Mainland Area: Refer to table 1 and table 4.

(4) Major shareholders information

Major shareholders information: Refer to table 7.

14. SEGMENT INFORMATION

(1) General information

The management of the Group has identified the operating segments based on how the Company’s Chief Operating Decision-Maker regularly reviews information in order to make decisions. The Chief Operating Decision-Maker manages the Group’s business from geographical and functional perspectives. Geographically, the Group focuses on its sales business in the U.S., Europe and Asia. In addition, the Group categorized its business units into manufacture, sales, research and development and investment management functions, and combines its segments that meet the disclosure threshold as “Others”.

~49~

(2) Segment information

The segment information provided to the Chief Operating Decision-Maker for the reportable segments is as follows:

segments is as follows:
Segment revenue Revenue from internal customers Revenue from external customers `－`API Income －Injection Product Income `－`Technical Service Income `－`Other Operating Income Interest income Depreciation and amortisation Interest expense Income from segment before income tax Segment assets Other acquisition of non-current assets Segment liabilities Segment revenue Revenue from internal customers Revenue from external customers `－`API Income －Injection Product Income `－`Technical Service Income `－`Other Operating Income Interest income Depreciation and amortisation Interest expense Income from segment before income tax Segment assets Other acquisition of non-current assets Segment liabilities	For the nine-monthperiod endedSeptember30,2024
	ScinoPharm SciAnda (Changshu) Taiwan,Ltd. PharmaceuticalsLtd. Others Total 2,176,669 $ 518,626 $ 12,076 $ 2,707,371 $ 9,571 317,323 10,669 337,563 2,167,098 201,303 1,407 2,369,808 1,890,615 196,868 52 2,087,535 58,991 - - 58,991 182,324 4,435 1,355 188,114 35,168 - - 35,168 44,783 319 136 45,238 280,726 83,259 820 364,805 5,473 528 - 6,001 277,175 34,537 1,267 312,979 10,126,488 1,747,161 33,799 11,907,448 121,954 93,938 18 215,910 1,230,305 129,610 9,576 1,369,491 For the nine-monthperiod endedSeptember30,2023			Total
	ScinoPharm Taiwan,Ltd. 1,929,140 $ 32,574 1,896,566 1,761,436 40,084 79,385 15,661 39,379 270,664 5,052 165,940 10,006,424 151,800 1,254,995	SciAnda (Changshu) Pharmaceuticals Ltd. 512,999 $ 381,724 131,275 115,571 - 15,704 - 290 72,367 2,003 21,629 1,774,408 62,998 206,768	Others 45,848 $ 10,770 35,078 34,899 - 179 - 148 912 - 915 27,157 1,393 4,580	Total
				2,487,987 $ 425,068 2,062,919 1,911,906 40,084 95,268 15,661 39,817 343,943 7,055 188,484 11,807,989 216,191 1,466,343

~50~

(3) Reconciliation for segment

A. The sales between segments were at arms’ length. The external revenues reported to the Chief Operating Decision-Maker adopt the same measurement basis for revenues in the statement of comprehensive income. The reconciliations of pre-tax income between reportable segments and continuing operations were as follows :

		Forthenine-monthperiods ended September30,	Forthenine-monthperiods ended September30,	Forthenine-monthperiods ended September30,	Forthenine-monthperiods ended September30,	Forthenine-monthperiods ended September30,
			2024			2023
Reportable segments profit before		$	311,712		$	187,569
income tax
Other segments income before income
tax			1,267			915
Internal segments transaction elimination	(		13,754)	(		30,598)
Profit before income tax		$	299,225		$	157,886

B. The amount of total assets provided to the Chief Operating Decision-Maker adopts the same measurement for assets in the Group's financial statements. A reconciliation of assets of reportable segments and total assets is as follows:

			September30,2024			September30,2023
Assets of reportable segments		$	11,873,649		$	11,780,832
Assets of other operating segments			33,799			27,157
Internal segment transaction elimination	(		123,144)	(		240,895)
Total assets		$	11,784,304		$	11,567,094

C. The amount of total liabilities provided to the Chief Operating Decision-Maker adopts the same measurement for liabilities in the Group's financial statements. A reconciliation of liabilities of reportable segments and total liabilities is as follows:

			September30,2024			September30,2023
Liabilities of reportable segments		$	1,359,915		$	1,461,763
Liabilities of other operating segments			9,576			4,580
Internal segment transaction elimination	(		25,093)	(		141,631)
Total liabilities		$	1,344,398		$	1,324,712

~51~

ScinoPharm Taiwan, Ltd. and Subsidiaries

Table 1

Expressed in thousands of NTD

Provision of endorsements and guarantees to others

For the nine-month period ended September 30, 2024

Number	Endorser/ guarantor	Party being endorsed/guaranteed	Party being endorsed/guaranteed	Limit on endorsements/ guarantees provided for a single party （Note 2）	Maximum outstanding endorsement/ guarantee amount during theperiod	Outstanding endorsement/ guarantee amount at September 30, 2024	Actual amount drawn down	Amount of endorsements/ guarantees secured with collateral	Ratio of accumulated endorsement/ guarantee amount to net asset value of the endorser/ guarantor company	Ceiling on total amount of endorsements/ guarantees provided （Note 2）	Provision of endorsements/ guarantees by parent company to subsidiary	Provision of endorsements/ guarantees by subsidiary to parent company	Provision of endorsements/ guarantees to the party in Mainland China	Footnote
		Companyname	Relationship with the endorser/ guarantor （Note 1）
0	ScinoPharm Taiwan, Ltd.	SciAnda (Changshu) Pharmaceuticals, Ltd.	1	10,439,906 $	483,238 $	180,375 $	- $	- $	1.73%	10,439,906 $	Y	N	Y	`－`

Note 1: The following code represents the relationship with the Company:

1.A company in which the Company directly and indirectly holds 50% of the voting shares.
Note 2: 1.The limit of total amount of endorsement is 50% of the Company's net worth, for 100% directly or indirectly owned subsidiaries, the maximum amount is 100% of its net worth.
The limit of total amount of the Group's endorsement and guarantee is 100% of the Group's net worth.
2.For any endorsement or guarantee provided by the Company due to business dealings, the amount of endorsement or guarantees shall be limited to the business dealing amount of the most recent year or the current year. The business dealing amount is product purchase or sale amount between the entities, whichever is higher.

Note 3: The numbers in the table that involves foreign currencies are expressed in New Taiwan Dollars according to the exchange rate posted on the date of the consolidated financial statements (CNY:NTD 1:4.509 ； USD:NTD 1:31.65).

Table 1, Page 1

ScinoPharm Taiwan, Ltd. and Subsidiaries

Holding of marketable securities at the end of the period (not including subsidiaries, associates and joint ventures) September 30, 2024

			September 30,	2024
Table 2 Securities held by	Marketable securities	Relationship with the securities issuer	General ledger account		As ofSeptember30,2024		Fairvalue Footnote Expressed in thousands of NTD
				Number of shares	Bookvalue	Ownership (%)	Fairvalue
ScinoPharm Taiwan, Ltd.	Stocks: Tanvex Biologics, Inc. SYNGEN, INC.	The Company is a director of Tanvex Biologics, Inc. `－`	Financial assets at fair value through other comprehensive income - non-current Financial assets at fair value through profit or loss - non-current	28,800,000 245,000	74,564 $ -	16.84% 7.40%	74,564 $ -	`－` `－`

Table 2, Page 1

Table 3

Expressed in thousands of NTD

ScinoPharm Taiwan, Ltd. and Subsidiaries

Purchases or sales of goods from or to related parties reaching $100 million or 20% of paid in capital or more For the nine-month period ended September 30, 2024

Purchaser/seller	Counterparty	Relationship with the counterparty			Transaction		Differences in transaction terms compared to third party transactions	Differences in transaction terms compared to third party transactions	Notes/accounts receivable(payable)	Notes/accounts receivable(payable)	Footnote
			Purchases(sales)	Amount	Percentage of total purchases(sales)	Credit term	Unitprice	Credit term	Balance	Percentage of total notes/accounts receivable(payable)
ScinoPharm Taiwan, Ltd. SciAnda (Changshu) Pharmaceuticals, Ltd.	SciAnda (Changshu) Pharmaceuticals, Ltd. ScinoPharm Taiwan, Ltd.	Subsidary The Company	Purchases (Sales)	320,946 $ 320,946) (	39% (62%)	Closes its accounts 90 days from the end of each month Closes its accounts 90 days from the end of each month	- $ -	`－` `－`	18,877) ($ 18,877	(15%) 37%	`－` `－`

Table 3, Page 1

Table 4

Expressed in thousands of NTD

ScinoPharm Taiwan, Ltd. and Subsidiaries

- Significant inter company transactions during the reporting period For the nine-month period ended September 30, 2024

Number (Note 2)	Companyname	Counterparty	Relationship (Note3)		Transactions	Transactions
				General ledger account	Amount	Transaction terms	Percentage of consolidated total operating revenues or total assets(Note 4)
0	ScinoPharm Taiwan, Ltd.	SciAnda (Changshu) Pharmaceuticals, Ltd.	1 1 1	Purchases Accounts Payable Endorsements and guarantees	320,946 $ 18,877 180,375	Closes its accounts 90 days from the end of each month `－` `－`	14% `－` 2%

Note 1: Significant inter-company transactions during the reporting periods are not disclosed since these were corresponding transactions. Only transactions over NT$10 million are material.
Note 2: The numbers filled in for the transaction company in respect of inter-company transactions are as follows:
(1) Parent company is ‘0’.
(2) The subsidiaries are numbered in order starting from ‘1’.
Note 3: Relationship between transaction company and counterparty is classified into the following three categories:
(1) Parent company to subsidiary.
(2) Subsidiary to parent company.
(3) Subsidiary to subsidiary.
Note 4: Regarding percentage of transaction amount to consolidated total operating revenues or total assets, it is computed based on period-end balance of transaction to consolidated total assets for balance sheet accounts and based on accumulated transaction amount for the period to consolidated total operating revenues for income statement accounts.
Note 5: The numbers in the table that involves foreign currencies are expressed in New Taiwan Dollars according to the exchange rate posted on the date of the consolidated financial statements (CNY:NTD 1:4.509 ； USD:NTD 1:31.65).

Table 4, Page 1

ScinoPharm Taiwan, Ltd. and Subsidiaries

Expressed in thousands of NTD

Names, locations and other information of investee companies (not including investees in Mainland China) For the nine-month period ended September 30, 2024

Table 5

Investor	Investee	Location	Main business activities	Initial investment amount	Initial investment amount	Shares held	as atSeptember30,2024	as atSeptember30,2024	Net profit of the investee for the nine-month period endedSeptember30,2024	Investment income recognised by the Company for the nine-month period endedSeptember30,2024	Footnote
				Balance as at September30,2024	Balance as at December31,2023	Number of shares	Ownership (%)	Bookvalue
ScinoPharm Taiwan, Ltd.	SPT International, Ltd. ScinoPharm Singapore Pte Ltd.	Tortola, British Virgin Islands Singapore	Professional investment Professional investment	3,614,585 $ -	3,614,585 $ -	118,524,644 2	100.00 100.00	1,543,502 $ 220	35,711 $ 31	21,957 $ 31	Subsidiary Subsidiary

Table 5, Page 1

ScinoPharm Taiwan, Ltd. and Subsidiaries

Table 6

Expressed in thousands of NTD

Information on investments in Mainland China `－` Basic information

For the nine-month period ended September 30, 2024

Investee in Mainland China	Main business activities	Paid-in capital	Investment method	Accumulated amount of remittance from Taiwan to Mainland China as of January 1, 2024	Amount remitted from Taiwan to Mainland China/ Amount remitted back to Taiwan for the nine-month period ended September 30,2024	Amount remitted from Taiwan to Mainland China/ Amount remitted back to Taiwan for the nine-month period ended September 30,2024	Accumulated amount of remittance from Taiwan to Mainland China as of September 30,2024	Net income of investee for the nine-month period ended September 30,2024	Ownership held by the Company (direct or indirect)	Investment income recognised by the Company for the nine-month period ended September 30,2024	Book value of investments in Mainland China as of September 30, 2024	Accumulated amount of investment income remitted back to Taiwan as of September 30, 2024	Footnote
					Remitted to Mainland China	Remitted back to Taiwan
SciAnda (Changshu) Pharmaceuticals, Ltd. SciAnda Shanghai Biochemical Technology, Ltd.	Research, development, and manufacture of API and new drugs, sale produced products, etc. Import, export and sales of API and intermediates, etc.	3,687,225 $ 37,980	`（`Note 1`）` `（`Note 1`）`	3,678,503 $ 37,980	- $ -	- $ -	3,678,503 $ 37,980	34,537 $ 1,158	100% 100%	34,537 $ 1,158	1,617,550 $ 20,860	- $ -	Subsidary (Note 2) Subsidary (Note 3)

Accumulated amount of Investment amount approved by remittance from Taiwan to the Investment Commission of Ceiling on investments in Mainland Mainland China the Ministry of Economic China imposed by the Investment Company name as of September 30, 2024 Affairs (MOEA) Commission of MOEA (Note 4) ScinoPharm $ 3,755,225 $ 3,755,225 $ 6,263,944 Taiwan, Ltd.

Note 1: Indirect investment in Mainland China through a company set up in a third region, SPT International, Ltd. Note 2: The investment income recognised by the Company for the nine-month period ended September 30, 2024 was based on reviewed financial statements of investee companies as of and for the nine-month period ended September 30, 2024.

Note 3: The investment income recognised by the Company for the nine-month period ended September 30, 2024 was based on unreviewed financial statements of investee companies as of and for nine-month period ended September 30, 2024. Note 4: The ceiling amount is 60% of the higher of net worth or consolidated net worth.

Table 6, Page 1

ScinoPharm Taiwan, Ltd. and Subsidiaries Major shareholders information September 30, 2024

Name of the keyshareholder Table 7	Number of	shares	Ownership (%)	Footnote Expressed in shares
	Common stock	Preferred stock
Uni-President Enterprises Corp. National Development Fund, Executive Yuan	299,968,639 109,539,014	`－` `－`	37.94% 13.85%	`－` `－`

Note: The major shareholders information was derived from the data that the Company issued common shares (including treasury shares) and preference shares in dematerialised form which were registered and held by the shareholders above 5% on the last operating date of each quarter and was calculated by Taiwan Depository & Clearing Corporation.

The share capital which was recorded in the financial statements is different from the actual number of shares issued in dematerialised form because of the difference in the calculation basis.

Table 7, Page 1

AI assistant

SPT — Interim / Quarterly Report 2024

51922_rns_2024-12-23_ae1d0cc0-505c-4d6e-81ef-1ea43ba0077a.pdf

INDEPENDENT AUDITORS’ REVIEW REPORT TRANSLATED FROM CHINESE

Introduction

Scope of review

Basis for qualified conclusion

Qualified conclusion

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

SEPTEMBER 30, 2024, DECEMBER 31, 2023 AND SEPTEMBER 30, 2023

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

SEPTEMBER 30, 2024, DECEMBER 31, 2023 AND SEPTEMBER 30, 2023

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2024 AND 2023

1. HISTORY AND ORGANISATION

STATEMENTS AND PROCEDURES FOR AUTHORIZATION

4. SUMMARY OF MATERIAL ACCOUNTING POLICIES

(1) Compliance statement

(2) Basis of preparation

(3) Basis of consolidation

B. Subsidiaries included in the consolidated financial statements:

(4) Employee benefits

Defined benefit plans

(5) Income tax

5. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY

6. DETAILS OF SIGNIFICANT ACCOUNTS

(1) CASH AND CASH EQUIVALENTS

(2) FINANCIAL ASSETS AND LIABILITIES AT FAIR VALUE THROUGH PROFIT OR LOSS

(4) INVENTORIES

(5) FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME -

NON-CURRENT

(6) PROPERTY, PLANT AND EQUIPMENT

(8) Impairment of non-financial assets

(9) SHORT-TERM BORROWINGS

(10) OTHER PAYABLES

(11) PENSIONS

(12) SHARE CAPITAL

(13) CAPITAL RESERVES

(14) SHARE-BASED PAYMENT – EMPLOYEES’ COMPENSATION

B. Details of the share-based payment arrangements are as follows:

(15) RETAINED EARNINGS

(16) OTHER EQUITY ITEMS

(17) OPERATING REVENUE

A. Disaggregation of revenue from contracts with customers

(18) INTEREST INCOME

(19) OTHER INCOME

(20) OTHER GAINS AND LOSSES

(21) FINANCE COSTS

(22) EXPENSES BY NATURE

(24) INCOME TAX

A. Income tax expense

(25) EARNINGS PER SHARE (“EPS”)

(26) SUPPLEMENTAL CASH FLOW INFORMATION

A. Investing activities with partial cash payments:

B. Investing activities with no cash flow effects:

(27) CHANGES IN LIABILITIES FROM FINANCING ACTIVITIES

7. RELATED PARTY TRANSACTIONS

(1) Parent and ultimate controlling party

Names of related parties

Relationship with the Company

(3) Significant transactions and balances with related parties

(4) Key management compensation

8. PLEDGED ASSETS

9. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNISED CONTRACT

COMMITMENTS

10. SIGNIFICANT DISASTER LOSS: None.

11. SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE: None.

12. OTHERS

(2) Financial instruments

II. Price risk

III. Cash flow and fair value interest rate risk

(b) Credit risk

(c) Liquidity risk

(3) Fair value information

13. SUPPLEMENTARY DISCLOSURES

(1) Significant transactions information

(2) Information on investees

SPT Interim / Quarterly Report 2024

Information on investments in Mainland China `－` Basic information